

**BEFORE THE  
BOARD OF PHARMACY  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA**

**In the Matter of the Accusation Against:**

**TALAMI INTERNATIONAL, INC., dba PALM CARE PHARMACY;  
USAMA ALKAZAKI, CEO/SECRETARY/CFO,  
Pharmacy Permit No. PHY 53746;**

**TALAMI HEALTH CARE LLC, dba PALM CARE PHARMACY;  
USAMA ALKAZAKI, MEMBER,  
Pharmacy Permit No. PHY 56207;**

**USAMA ALKAZAKI,  
Pharmacist License No. RPH 69696,  
Advance Practice Pharmacist License No. APH 10659;**

**SARAH ADEL ABDULKAREEM KALA,  
Pharmacist License No. RPH 76476;**

**BRENDA OFELIA CORTEZ-GOMEZ,  
Pharmacist License No. RPH 67947,**

**Respondents.**

**Agency Case No. 7033**

**OAH No. 2022030976**

**and**

**In the Matter of the Statement of Issues Against:**

**TALAMI INTERNATIONAL HEALTH LLC,  
dba PALM CARE PHARMACY,  
Applicant for Pharmacy Permit,**

**Respondent.**

**Case No. 7070**

**and**

**In the Matter of the Statement of Issues Against:**

**DREAM BORDER VILLAGE, LLC, dba PALM CARE PHARMACY 1005,  
Applicant for Pharmacy Permit,**

**Respondent.**

**Case No. 7432**

## DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order for Public Repeval is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on January 16, 2025.

It is so ORDERED on December 17, 2024.

BOARD OF PHARMACY  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA

By

A handwritten signature in black ink, appearing to read "Seung W. Oh". The signature is written in a cursive style with a large initial "S".

Seung W. Oh, Pharm.D.  
Board President

1 ROB BONTA  
Attorney General of California  
2 GREGORY J. SALUTE  
Supervising Deputy Attorney General  
3 MICHAEL M. KARIMI  
Deputy Attorney General  
4 State Bar No. 260906  
600 West Broadway, Suite 1800  
5 San Diego, CA 92101  
P.O. Box 85266  
6 San Diego, CA 92186-5266  
Telephone: (619) 738-9607  
7 Facsimile: (619) 645-2061  
E-mail: Michael.Karimi@doj.ca.gov  
8 *Attorneys for Complainant*

9 **BEFORE THE**  
10 **BOARD OF PHARMACY**  
11 **DEPARTMENT OF CONSUMER AFFAIRS**  
12 **STATE OF CALIFORNIA**

13 In the Matter of the Accusation Against:

14 **TALAMI INTERNATIONAL, INC., DBA**  
15 **PALM CARE PHARMACY; USAMA**  
16 **ALKAZAKI, CEO/SECRETARY/CFO**  
17 **505 N. Mollison Avenue, Ste. 102**  
18 **El Cajon, CA 92021**

19 **Pharmacy Permit No. PHY 53746**

20 **TALAMI HEALTH CARE LLC, DBA**  
21 **PALM CARE PHARMACY; USAMA**  
22 **ALKAZAKI MEMBER**  
23 **101 N. Highland Ave, Ste E, F, G**  
24 **National City, CA 91950**

25 **Pharmacy Permit No. PHY 56207**

26 **USAMA ALKAZAKI**  
27 **1724 Horizon Heights Circle**  
28 **El Cajon, CA 92019**

**Pharmacist License No. RPH 69696**  
**Advance Practice Pharmacist License No.**  
**APH 10659**

**SARAH ADEL ABDULKAREEM KALA**  
**3911 Paseo Tamayo**  
**La Mesa, CA 91941**

**Pharmacist License No. RPH 76476**

Case No. 7033

OAH No. 2022030976

**STIPULATED SETTLEMENT AND**  
**DISCIPLINARY ORDER FOR PUBLIC**  
**REPROVAL (AS TO BRENDA OFELIA**  
**CORTEZ-GOMEZ ONLY)**

**[Bus. & Prof. Code § 495]**

1 **BRENDA OFELIA CORTEZ-GOMEZ**  
2 **1140 Chimney Flats Lane**  
3 **Chula Vista, CA 91915**

4 **Pharmacist License No. RPH 67947**

5 Respondents.

6 In the Matter of the Statement of Issues  
7 Against:

8 **TALAMI INTERNATIONAL HEALTH**  
9 **LLC, DBA PALM CARE PHARMACY**

10 **Applicant for Pharmacy Permit**

11 Respondent.

Case No. 7070

12 In the Matter of the Statement of Issues  
13 Against:

14 **DREAM BORDER VILLAGE, LLC, DBA**  
15 **PALM CARE PHARMACY 1005**

16 **Applicant for Pharmacy Permit**

17 Respondent.

Case No. 7432

18 IT IS HEREBY STIPULATED AND AGREED by and between Executive Officer Anne  
19 Sodergren and Respondent Brenda Ofelia Cortez-Gomez, parties to the above-entitled  
20 proceedings that the following matters are true:

21 **PARTIES**

22 1. Anne Sodergren (Complainant) is the Executive Officer of the Board of Pharmacy  
23 (Board). She brought this action solely in her official capacity and is represented in this matter by  
24 Rob Bonta, Attorney General of the State of California, by Michael M. Karimi, Deputy Attorney  
25 General.

26 2. Respondent Brenda Ofelia Cortez-Gomez (Respondent Cortez-Gomez) is represented  
27 in this proceeding by attorney Tony J. Park of California Pharmacy Lawyers, whose address is:  
28 9090 Irvine Center Drive, Irvine, CA 92618-4658.

1 **JURISDICTION**

2 3. On or about August 29, 2012, the Board issued Pharmacist License Number RPH  
3 67947 to Respondent Cortez-Gomez. The Pharmacist License was in full force and effect at all  
4 times relevant to the charges brought herein and will expire on May 31, 2026, unless renewed.

5 4. Third Amended Accusation No. 7033 was filed before the Board and is currently  
6 pending against Respondent Cortez-Gomez. The Third Amended Accusation and all other  
7 statutorily required documents were properly served on Respondent Cortez-Gomez on June 4,  
8 2024. Respondent Cortez-Gomez timely filed her Notice of Defense contesting the Accusation.  
9 A copy of Third Amended Accusation No. 7033 is attached as Exhibit A and incorporated herein  
10 by reference.

11 **ADVISEMENT AND WAIVERS**

12 5. Respondent Cortez-Gomez has carefully read, fully discussed with counsel, and  
13 understands the charges and allegations in Third Amended Accusation No. 7033. Respondent  
14 Cortez-Gomez has also carefully read, fully discussed with counsel, and understands the effects  
15 of this Stipulated Settlement and Disciplinary Order for Public Repeval.

16 6. Respondent Cortez-Gomez is fully aware of her legal rights in this matter, including  
17 the right to a hearing on the charges and allegations in the Third Amended Accusation; the right  
18 to be represented by counsel at her own expense; the right to confront and cross-examine the  
19 witnesses against her; the right to present evidence and to testify on her own behalf; the right to  
20 the issuance of subpoenas to compel the attendance of witnesses and the production of  
21 documents; the right to reconsideration and court review of an adverse decision; and all other  
22 rights accorded by the California Administrative Procedure Act and other applicable laws.

23 7. Respondent Cortez-Gomez voluntarily, knowingly, and intelligently waives and gives  
24 up each and every right set forth above.

25 **CULPABILITY**

26 8. Respondent Cortez- Gomez admits the truth of each and every charge and allegation  
27 in Third Amended Accusation No. 7033.

28 ///



1 **DISCIPLINARY ORDER**

2 IT IS HEREBY ORDERED that Pharmacist License No. RPH 67947 issued to Respondent  
3 Brenda Ofelia Cortez-Gomez (Respondent Cortez-Gomez) shall be publicly reprovved by the  
4 Board of Pharmacy under Business and Professions Code section 495 in resolution of Third  
5 Amended Accusation No. 7033, attached as Exhibit A.

6 **Coursework.** Within sixty calendar days of the effective date of the Decision, Respondent  
7 Cortez-Gomez shall enroll in a course in ethics, at Respondent Cortez-Gomez’s expense,  
8 approved in advance by the Board or its designee, which complies with Title 16, California Code  
9 of Regulations, section 1773.5. Respondent Cortez-Gomez shall provide proof of enrollment  
10 upon request. Within five days of the completion, Respondent Cortez-Gomez shall submit a copy  
11 of the certificate of completion to the Board or its designee. If Respondent Cortez-Gomez fails to  
12 timely enroll in an approved ethics course, successfully complete the course within two years, and  
13 timely submit proof of completion, Respondent Cortez-Gomez shall not be allowed to renew her  
14 Pharmacist License until she has completed the ethics course.

15 **No Ownership or Management of Licensed Premises for Five Years.** Respondent  
16 Cortez-Gomez shall not acquire any ownership, legal or beneficial interest nor serve as a manager  
17 (including pharmacist-in-charge), administrator, member, officer, director, trustee, associate, or  
18 partner of any business, firm, partnership, or corporation licensed by the Board for five years after  
19 the effective date of this decision. Violation of this restriction shall be considered a violation of  
20 this Stipulated Settlement and Disciplinary Order for Public Reapproval.

21 **Full Compliance.** As a resolution of the charges in Third Amended Accusation No. 7033,  
22 this stipulated settlement is contingent upon Respondent Cortez-Gomez’s full compliance with all  
23 conditions of this Order. If Respondent Cortez-Gomez fails to satisfy any of these conditions,  
24 such failure to comply constitutes cause for discipline, including outright revocation, of  
25 Respondent Cortez-Gomez’s Pharmacist License No. RPH 67947.

26 **ACCEPTANCE**

27 I have carefully read the above Stipulated Settlement and Disciplinary Order for Public  
28 Reapproval and have fully discussed it with my attorney, Tony J. Park. I understand the stipulation



1 and the effect it will have on my Original Pharmacy Permit. I enter into this Stipulated  
2 Settlement and Disciplinary Order for Public Repeval voluntarily, knowingly, and intelligently,  
3 and agree to be bound by the Decision and Order of the Board of Pharmacy, .

4  
5 DATED: \_\_\_\_\_  
6 BRENDA OFELIA CORTEZ-GOMEZ  
*Respondent*

7 I have read and fully discussed with Respondent Brenda Ofelia Cortez-Gomez the terms  
8 and conditions and other matters contained in the above Stipulated Settlement and Disciplinary  
9 Order for Public Repeval. I approve its form and content.

10  
11 DATED: \_\_\_\_\_  
12 TONY J. PARK  
*Attorney for Respondent*

13 **ENDORSEMENT**

14 The foregoing Stipulated Settlement and Disciplinary Order for Public Repeval is hereby  
15 respectfully submitted for consideration by the Board of Pharmacy, of the Department of  
16 Consumer Affairs.

17  
18 DATED: \_\_\_\_\_ Respectfully submitted,  
19 ROB BONTA  
Attorney General of California  
20 GREGORY J. SALUTE  
Supervising Deputy Attorney General

21  
22  
23 MICHAEL M. KARIMI  
Deputy Attorney General  
*Attorneys for Complainant*

24  
25  
26  
27 SD2020801187  
84761935.docx

1 and the effect it will have on my Original Pharmacy Permit. I enter into this Stipulated  
2 Settlement and Disciplinary Order for Public Repeval voluntarily, knowingly, and intelligently,  
3 and agree to be bound by the Decision and Order of the Board of Pharmacy, .

4  
5 DATED: 10/2/2024

DocuSigned by:  
*Brenda Ofelia Cortez-Gomez*  
A332EBF0F745405...  
BRENDA OFELIA CORTEZ-GOMEZ  
Respondent

7 I have read and fully discussed with Respondent Brenda Ofelia Cortez-Gomez the terms  
8 and conditions and other matters contained in the above Stipulated Settlement and Disciplinary  
9 Order for Public Repeval. I approve its form and content.

10  
11 DATED: 10/2/2024

DocuSigned by:  
*Tony J. Park*  
BBF9CC7A091B410...  
TONY J. PARK  
Attorney for Respondent

12  
13 **ENDORSEMENT**

14 The foregoing Stipulated Settlement and Disciplinary Order for Public Repeval is hereby  
15 respectfully submitted for consideration by the Board of Pharmacy, of the Department of  
16 Consumer Affairs.

17 DATED: October 7, 2024

18 Respectfully submitted,  
19 ROB BONTA  
Attorney General of California  
20 GREGORY J. SALUTE  
Supervising Deputy Attorney General

21  
22   
23 MICHAEL M. KARIMI  
Deputy Attorney General  
24 Attorneys for Complainant

25  
26 SD2020801187  
27 84761935.docx

**Exhibit A**

**Third Amended Accusation No. 7033, Third Amended Statement of Issues No. 7070 and  
Second Amended Statement of Issues No. 7432**

1 ROB BONTA  
Attorney General of California  
2 GREGORY J. SALUTE  
Supervising Deputy Attorney General  
3 MICHAEL M. KARIMI  
Deputy Attorney General  
4 State Bar No. 260906  
600 West Broadway, Suite 1800  
5 San Diego, CA 92101  
P.O. Box 85266  
6 San Diego, CA 92186-5266  
Telephone: (619) 738-9607  
7 Facsimile: (619) 645-2061  
E-mail: Michael.Karimi@doj.ca.gov  
8 *Attorneys for Complainant*

9 **BEFORE THE**  
10 **BOARD OF PHARMACY**  
11 **DEPARTMENT OF CONSUMER AFFAIRS**  
12 **STATE OF CALIFORNIA**

13 In the Matter of the Accusation Against:  
14 **TALAMI INTERNATIONAL, INC., DBA**  
15 **PALM CARE PHARMACY; USAMA**  
16 **ALKAZAKI, CEO/SECRETARY/CFO**  
17 **505 N. Mollison Avenue, Ste. 102**  
18 **El Cajon, CA 92021**

19 **Pharmacy Permit No. PHY 53746**

20 **TALAMI HEALTH CARE LLC, DBA**  
21 **PALM CARE PHARMACY; USAMA**  
22 **ALKAZAKI MEMBER**  
23 **101 N. Highland Ave, Ste E, F, G**  
24 **National City, CA 91950**

25 **Pharmacy Permit No. PHY 56207**

26 **USAMA ALKAZAKI**  
27 **1724 Horizon Heights Circle**  
28 **El Cajon, CA 92019**

**Pharmacist License No. RPH 69696**  
**Advance Practice Pharmacist License No.**  
**APH 10659**

**SARAH ADEL ABDULKAREEM KALA**  
**3911 Paseo Tamayo**  
**La Mesa, CA 91941**

**Pharmacist License No. RPH 76476**

**BRENDA OFELIA CORTEZ-GOMEZ**  
**1140 Chimney Flats Lane**  
**Chula Vista, CA 91915**

**Pharmacist License No. RPH 67947**

Respondents.

Case No. 7033

**THIRD AMENDED ACCUSATION**

1 In the Matter of the Statement of Issues  
2 Against:  
3 **TALAMI INTERNATIONAL HEALTH**  
4 **LLC, DBA PALM CARE PHARMACY**  
5 **Applicant for Pharmacy Permit**  
Respondent.

Case No. 7070

**THIRD AMENDED STATEMENT OF ISSUES**

6 In the Matter of the Statement of Issues  
7 Against:  
8 **DREAM BORDER VILLAGE, LLC, DBA**  
9 **PALM CARE PHARMACY 1005**  
10 **Applicant for Pharmacy Permit**  
Respondent.

Case No. 7432

**SECOND AMENDED STATEMENT OF ISSUES**

**PARTIES**

11  
12 1. Anne Sodergren (Complainant) brings this Third Amended Accusation, Third  
13 Amended Statement of Issues, and Second Amended Statement of Issues, solely in her official  
14 capacity as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs  
15 (Board).

16 2. On or about August 14, 2015, the Board issued Pharmacy Permit Number PHY  
17 53746 to Talami International, Inc., dba Palm Care Pharmacy (Respondent Palm Care). Usama  
18 Alkazaki (Respondent Alkazaki) has served, or been listed in Board records, as the sole  
19 shareholder and Chief Executive Officer of Talami International, Inc., and as Pharmacist-in-  
20 Charge of the pharmacy since the issuance of Pharmacy Permit Number PHY 53746. The  
21 Pharmacy Permit was in full force and effect at all times relevant to the charges brought herein  
22 and will expire on August 1, 2024, unless renewed.

23 3. On or about September 27, 2018, the Board issued Pharmacy Permit Number PHY  
24 56207 to Talami Health Care LLC, dba Palm Care Pharmacy (Respondent Palm Care National  
25 City). Respondent Alkazaki has served, or been listed in Board records, as a Member of Talami  
26 Health Care LLC, and as Pharmacist-in-Charge of the pharmacy since the issuance of Pharmacy  
27 Permit Number PHY 56207. The Pharmacy Permit was in full force and effect at all times  
28 relevant to the charges brought herein and will expire on September 1, 2024, unless renewed.

1           4.     On or about September 5, 2013, the Board issued Pharmacist License Number RPH  
2 69696 to Respondent Alkazaki. The Pharmacist License was in full force and effect at all times  
3 relevant to the charges brought herein and will expire on June 30, 2025, unless renewed.

4           5.     On or about February 12, 2020, the Board issued Advance Practice Pharmacist  
5 License Number APH 10659 to Respondent Alkazaki. The Advance Practice Pharmacist License  
6 was in full force and effect at all times relevant to the charges brought herein and will expire on  
7 June 30, 2025, unless renewed.

8           6.     On or about May 24, 2017, the Board issued Pharmacist License Number RPH 76476  
9 to Sarah Adel Abdulkareem Kala (Respondent Kala). Respondent Kala was a staff pharmacist at  
10 Palm Care. The Pharmacist License was in full force and effect at all times relevant to the  
11 charges brought herein and will expire on June 30, 2024, unless renewed.

12          7.     On or about August 29, 2012, the Board issued Pharmacist License Number RPH  
13 67947 to Brenda Ofelia Cortez-Gomez (Respondent Cortez-Gomez). Respondent Cortez-Gomez  
14 was a staff pharmacist at Palm Care. The Pharmacist License was in full force and effect at all  
15 times relevant to the charges brought herein and will expire on May 31, 2024, unless renewed.

16          8.     On or about August 27, 2020, the Board received an application for a Community  
17 Pharmacy License from Talami International Health LLC, dba Palm Care Pharmacy. On or about  
18 August 12, 2020, Respondent Alkazaki certified under penalty of perjury to the truthfulness of all  
19 statements, answers, and representations in the application. The application identified  
20 Respondent Alkazaki as the Manager, CEO, sole owner of outstanding shares, and only member,  
21 manager, and officer of Talami International Health LLC. The Board denied the application on  
22 November 10, 2020.

23          9.     On or about October 21, 2022, the Board received an application for a pharmacy  
24 permit from Dream Border Village, LLC, dba Palm Care Pharmacy 1005. On or about December  
25 6, 2022, Amjad A. Alqazqi certified under penalty of perjury to the truthfulness of all statements,  
26 answers, and representations in the application. The application identified Respondent Alkazaki's  
27 brother, Amjad A. Alqazqi, as the Managing Member and sole owner of the outstanding shares of  
28 Dream Border Village, LLC. The Board denied the application on December 6, 2022.

**JURISDICTION**

10. This Third Amended Accusation, Third Amended Statement of Issues, and Second Amended Statement of Issues is brought before the Board under the authority of the following laws. All section references are to the Business and Professions Code (Code) unless otherwise indicated.

11. Section 4011 provides that the Board shall administer and enforce both the Pharmacy Law (Bus. & Prof. Code, § 4000 *et seq.*) and the Uniform Controlled Substances Act (Health & Safety Code, § 11000 *et seq.*).

12. Code section 4300 provides, in pertinent part, that every license issued by the Board is subject to discipline, including suspension or revocation, and that the Board may refuse a license to any applicant guilty of unprofessional conduct.

13. Code section 4300.1 provides, in pertinent part, that the expiration of a license shall not deprive the Board of jurisdiction to proceed with a disciplinary proceeding against the licensee or to render a decision imposing discipline on the license.

14. Code section 4302 provides, in pertinent part, that the Board may deny, suspend, or revoke any license where conditions exist in relation to any person holding 10 percent or more of the ownership interest or where conditions exist in relation to any officer, director, or other person with management or control of the license that would constitute grounds for disciplinary action against a licensee.

15. Section 4307 of the Code states:

(a) Any person who has been denied a license or whose license has been revoked or is under suspension, or who has failed to renew his or her license while it was under suspension, or who has been a manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control of any partnership, corporation, trust, firm, or association whose application for a license has been denied or revoked, is under suspension or has been placed on probation, and while acting as the manager, administrator, owner, member, officer, director, associate, partner, or any other person with management or control had knowledge of or knowingly participated in any conduct for which the license was denied, revoked, suspended, or placed on probation, shall be prohibited from serving as a manager, administrator, owner, member, officer, director, associate, partner, or in any other position with management or control of a licensee as follows:

(1) Where a probationary license is issued or where an existing license is placed on probation, this prohibition shall remain in effect for a period not to exceed five years.

(2) Where the license is denied or revoked, the prohibition shall continue until the license is issued or reinstated.

## INTRODUCTION

16. Palm Care Pharmacy dispenses drugs to patients in a retail setting known as a community pharmacy. Advertising locations in El Cajon, National City, and San Ysidro, the pharmacy targets immigrants who are Arabic speaking in San Diego County with social media posts written in Arabic, and videos posted to social media spoken in Arabic. Palm Care represents that its staff has “a firsthand understanding of the challenges faced by those navigating healthcare in a new country.” The pharmacy also describes itself as maintaining a “family atmosphere” where it knows and checks on its patients, wants to see them “healthy and happy” and will do “everything we can to assist with [their] wellbeing.”

17. Despite professing to have the best interests of its vulnerable population of patients at heart as if they were “family,” Palm Care Pharmacy was actually engaging in a variety of insurance fraud schemes while simultaneously endangering patients through repeated dispensing errors and dispensing adulterated drugs. When the Board investigated Respondents’ dispensing practices, Palm Care Pharmacy and its Pharmacist-in-Charge attempted to cover up their wrongdoing by altering pharmacy records and making false statements to the Board.

18. The Board’s eight investigations into Palm Care Pharmacy are identified in this pleading as the “*Molina*,” the “*Qlarant*” the “*Latuda*” and the “*La Maestra*” investigations (involving multiple forms of fraud and instances of record falsification), the “*La Mesa Cardiac Center*” investigation (fraud and a dispensing error), and the “*Patient M.A.*,” the “*Patient F.S.*,” and the “*Patient A.A.*” investigations (each involving prescription dispensing errors, but with patient F.S. also involving the alteration of records and the making of false statements to conceal the error, and with patient A.A. also involving Respondent Alkazaki calling A.A.’s household to dissuade them from continuing to cause the error to be investigated).

19. The Molina investigation primarily involved providers at the Neighborhood Healthcare clinic and prescriptions billed to insurer Molina Healthcare. Palm Care was engaged in a scheme of falsifying insurance approval requests to obtain insurance payments for hundreds of prescription fills for the newer and higher cost medication Metformin ER *Gastric* (brand name Glumetza), rather than the older and lower cost medication Metformin ER (brand name



1 Glucophage), even though it was only original Metformin ER that had actually been prescribed to  
2 the patients. In addition to this prescription fraud scheme, Respondent Alkazaki himself  
3 fraudulently billed 258 other medications to various insurers using the federally issued identifiers  
4 assigned to a Neighborhood Healthcare clinic nurse practitioner.

5 20. The Qlarant investigation uncovered that Palm Care National City had billed insurers  
6 for more Metformin ER Gastric than the pharmacy had itself purchased. The pharmacy's billings  
7 to insurers exceeded its purchases by 40,670 tablets in a zero-based audit of a 13-month period  
8 beginning January 1, 2020; the equivalent of 42.72% more in insurance billings than the total  
9 number of tablets actually purchased.<sup>1</sup> Moreover, Palm Care National City tried to cover-up this  
10 purchasing to sales discrepancy by furnishing falsified records to the Board reporting the  
11 purchase of 54,400 tablets under 37 unique "invoice numbers," from a supplier that had not ever  
12 sold the drug to the pharmacy.<sup>2</sup> The audit records the pharmacy furnished also revealed that it  
13 had been in the practice of incorrectly labeling its Metformin ER Gastric prescriptions under a  
14 NDC (National Drug Code) that did not match the tablets actually dispensed.

15 21. The Latuda investigation uncovered that Palm Care had billed insurers for more of  
16 the high-cost medication Lurasidone (brand name Latuda) than the pharmacy had itself  
17 purchased. The pharmacy's billings to insurers exceeded its purchases by 19,655 tablets in a  
18 zero-based audit of a 3-year period beginning April 27, 2020; the equivalent of 96.48% more in  
19 insurance billings than the total number of tablets actually purchased.

20 22. The La Maestra investigation uncovered more fraud, coming to the Board's attention  
21 through providers at La Maestra Community Health Center. First, providers reported that Palm  
22 Care was forging prescription authorizations related to six patients: M.K., S.S., C.B., I.M., I.S.,  
23 and K.B. Second, Palm Care's internally maintained *dispensing data* record showed the  
24 pharmacy was billing and dispensing drugs to patients at rates far in excess of the amount that had  
25 purportedly been authorized for a given period; in some instances at a rate more than triple the

26 <sup>1</sup> A zero-based audit, by starting from zero, does not account for starting inventory at the  
27 beginning of the audit period. Palm Care National City's inventory of the drug during a Board  
inspection conducted at the end of 2022 was approximately 7,300 tablets.

28 <sup>2</sup> Palm Care National City thus reported an acquisition total of 150,100 tablets in the audit period,  
54,900 more than the true number of 95,200 (accounting for 500 tablets purchased then returned).

1 purported prescriber authorization. Third, Palm Care records had been intentionally altered on at  
2 least one occasion to conceal a dispensing error to a patient S.O., and there were a wide variety of  
3 other significant discrepancies in the pharmacy's records indicating additional record alterations  
4 related to the unauthorized prescriptions dispensed to M.K., S.S., C.B., I.M., I.S., and K.B.

5 23. In the La Mesa Cardiac Center investigation, Palm Care dispensed a prescription for  
6 the drug furosemide incorrectly labeled as "blood thinner." Moreover, a review of Palm Care's  
7 internally maintained *dispensing data* record again revealed the pharmacy was billing and  
8 dispensing drugs to patients at rates far in excess of the amount that had purportedly been  
9 authorized for a given period, in one instances at a rate more than five times the purported  
10 authorization, and in two instances at more than two and a half times the purported authorization.

11 24. The patient M.A. investigation, the patient F.S. investigation, and the patient A.A.  
12 investigation each confirmed dispensing errors which caused harm to patients. In the case of  
13 patient M.A., the patient had been hospitalized after taking Metoprolol which Palm Care  
14 mistakenly dispensed instead of the prescribed drug metformin. In the subsequent error,  
15 involving patient F.S., Palm Care had incorrectly labeled the blood thinner Eliquis with the words  
16 "for diabetes," causing the patient exacerbated bleeding from a stomach ulcer after he repeatedly  
17 took the blood thinner to try to control his blood sugar. In the case of patient A.A., the patient  
18 took two blood pressure medications which Palm Care mistakenly dispensed to him, in addition  
19 to a third blood pressure medication which the patient was properly receiving from another  
20 pharmacy, causing the patient to experience lightheadedness.

21 25. Critically, with patient F.S., Palm Care tried to cover-up the error. Namely, Palm  
22 Care's *dispensing data* for patient F.S. was altered to omit any record of the dispensing error by  
23 the time of the Board's investigation into the complaint. When Respondent Alkazaki provided  
24 the altered record to the Board investigator, he also provided a written statement asserting F.S.  
25 had been mistaken in his belief that Palm Care had incorrectly labeled the medication. However,  
26 the Eliquis prescription dispensed to F.S. with the erroneous "for diabetes" direction was found in  
27 a prior version of Palm Care's *dispensing data* that was produced when the patient M.A.  
28 complaint was investigated.



1 (1) Knowingly present or cause to be presented any false or fraudulent claim for  
the payment of a loss under a contract of insurance.

2 (2) Knowingly prepare, make, or subscribe any writing, with intent to present or  
3 use the same, or to allow it to be presented or used in support of any false or  
fraudulent claim.

4 (b) It shall constitute cause for revocation or suspension of a license or  
5 certificate for a health care professional to engage in any conduct prohibited under  
Section 1871.4 of the Insurance Code or Section 549 or 550 of the Penal Code.

6 ...

7 31. Section 4022 of the Code states:

8 Dangerous drug or dangerous device means any drug or device unsafe for  
9 self-use in humans or animals, and includes the following:

10 (a) Any drug that bears the legend: Caution: federal law prohibits dispensing  
without prescription, Rx only, or words of similar import.

11 (b) Any device that bears the statement: Caution: federal law restricts this  
12 device to sale by or on the order of a \_\_\_\_\_, Rx only, or words of similar  
import, the blank to be filled in with the designation of the practitioner licensed to use  
13 or order use of the device.

14 (c) Any other drug or device that by federal or state law can be lawfully  
dispensed only on prescription or furnished pursuant to Section 4006.

15 32. Section 4059 of the Code states, in pertinent part, that a person may not furnish any  
16 dangerous drug except upon the prescription of a physician, dentist, podiatrist, optometrist,  
17 veterinarian, or naturopathic doctor pursuant to Section 3640.7.

18 33. Section 4063 of the Code states, that no prescription for any dangerous drug or  
19 dangerous device may be refilled except upon authorization of the prescriber. The authorization  
20 may be given orally or at the time of giving the original prescription. No prescription for any  
21 dangerous drug that is a controlled substance may be designated refillable as needed.

22 34. Section 4077 of the Code states, in pertinent part:

23 (a) Except as provided in subdivisions (b) and (c), no person shall dispense any  
24 dangerous drug upon prescription except in a container correctly labeled with the  
information required by Section 4076.

25 ...

26 35. Section 4076 of the Code states, in pertinent part:

27 (a) A pharmacist shall not dispense any prescription except in a container that meets  
28 the requirements of state and federal law and is correctly labeled with all of the following:

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

...

(2) The directions for the use of the drug.

...

36. Section 4040 of the Code states, in pertinent part:

(a) "Prescription" means an oral, written, or electronic transmission order that is both of the following:

(1) Given individually for the person or persons for whom ordered that includes all of the following:

...

(B) The name and quantity of the drug or device prescribed and the directions for use.

(C) The date of issue.

...

37. Section 4071 of the Code states:

Notwithstanding any other provision of law, a prescriber may authorize his or her agent on his or her behalf to orally or electronically transmit a prescription to the furnisher. The furnisher shall make a reasonable effort to determine that the person who transmits the prescription is authorized to do so and shall record the name of the authorized agent of the prescriber who transmits the order.

38. Code Section 4105 states, in pertinent part:

(a) All records or other documentation of the acquisition and disposition of dangerous drugs and dangerous devices by any entity licensed by the board shall be retained on the licensed premises in a readily retrievable form.

...

(d)(1) Any records that are maintained electronically shall be maintained so that the pharmacist-in-charge, or the pharmacist on duty if the pharmacist-in-charge is not on duty, shall, at all times during which the licensed premises are open for business, be able to produce a hardcopy and electronic copy of all records of acquisition or disposition or other drug or dispensing-related records maintained electronically.

...

39. Section 4125 of the Code states, in pertinent part:

(a) Every pharmacy shall establish a quality assurance program that shall, at a minimum, document medication errors attributable, in whole or in part, to the pharmacy or its personnel. The purpose of the quality assurance program shall be to assess errors that occur in the pharmacy in dispensing or furnishing prescription medications so that the pharmacy may take appropriate action to prevent a recurrence.

(b) Records generated for and maintained as a component of a pharmacy's ongoing quality assurance program shall be considered peer review documents and

1 not subject to discovery in any arbitration, civil, or other proceeding, except as  
2 provided hereafter. That privilege shall not prevent review of a pharmacy's quality  
3 assurance program and records maintained as part of that system by the board as  
4 necessary to protect the public health and safety or if fraud is alleged by a  
5 government agency with jurisdiction over the pharmacy. Nothing in this section shall  
6 be construed to prohibit a patient from accessing his or her own prescription records.  
7 Nothing in this section shall affect the discoverability of any records not solely  
8 generated for and maintained as a component of a pharmacy's ongoing quality  
9 assurance program.

10 ...

11 40. Code Section 4169, subdivision (a) states, in pertinent part:

12 (a) A person or entity shall not do any of the following:

13 ...

14 (2) Purchase, trade, sell, or transfer dangerous drugs or dangerous devices that the  
15 person knew or reasonably should have known were adulterated, as set forth in Article 2  
16 (commencing with Section 111250) of Chapter 6 of Part 5 of Division 104 of the Health  
17 and Safety Code.

18 ...

19 (5) Fail to maintain records of the acquisition or disposition of dangerous drugs or  
20 dangerous devices for at least three years.

21 ...

22 41. Section 4113 of the Code states, in pertinent part:

23 ...

24 (c) The pharmacist-in-charge shall be responsible for a pharmacy's compliance with  
25 all state and federal laws and regulations pertaining to the practice of pharmacy.

26 ...

27 42. Section 4301 of the Code states, in pertinent part:

28 The board shall take action against any holder of a license who is guilty of  
unprofessional conduct or whose license has been issued by mistake. Unprofessional  
conduct shall include, but is not limited to, any of the following:

...

(f) The commission of any act involving moral turpitude, dishonesty, fraud,  
deceit, or corruption, whether the act is committed in the course of relations as a  
licensee or otherwise, and whether the act is a felony or misdemeanor or not.

(g) Knowingly making or signing any certificate or other document that falsely  
represents the existence or nonexistence of a state of facts.

...

(j) The violation of any of the statutes of this state, of any other state, or of the  
United States regulating controlled substances and dangerous drugs.

...

(m) The cash compromise of a charge of violation of Chapter 13 (commencing

1 with Section 801) of Title 21 of the United States Code regulating controlled  
2 substances or of Chapter 7 (commencing with Section 14000) of Part 3 of Division 9  
3 of the Welfare and Institutions Code relating to the Medi-Cal program.

4 ...

5 (o) Violating or attempting to violate, directly or indirectly, or assisting in or  
6 abetting the violation of or conspiring to violate any provision or term of this chapter  
7 or of the applicable federal and state laws and regulations governing pharmacy,  
8 including regulations established by the board or by any other state or federal  
9 regulatory agency.

10 (p) Actions or conduct that would have warranted denial of a license.

11 (q) Engaging in any conduct that subverts or attempts to subvert an investigation of  
12 the board.

13 ...

14 43. Section 4306.5 of the Code states:

15 Unprofessional conduct for a pharmacist may include any of the following:

16 (a) Acts or omissions that involve, in whole or in part, the inappropriate  
17 exercise of his or her education, training, or experience as a pharmacist, whether or  
18 not the act or omission arises in the course of the practice of pharmacy or the  
19 ownership, management, administration, or operation of a pharmacy or other entity  
20 licensed by the board.

21 (b) Acts or omissions that involve, in whole or in part, the failure to exercise or  
22 implement his or her best professional judgment or corresponding responsibility with  
23 regard to the dispensing or furnishing of controlled substances, dangerous drugs, or  
24 dangerous devices, or with regard to the provision of services.

25 (c) Acts or omissions that involve, in whole or in part, the failure to consult  
26 appropriate patient, prescription, and other records pertaining to the performance of  
27 any pharmacy function.

28 (d) Acts or omissions that involve, in whole or in part, the failure to fully  
maintain and retain appropriate patient-specific information pertaining to the  
performance of any pharmacy function.

44. Section 4324 subsection (a) of the Code states, in pertinent part, that every person  
who signs the name of another, or of a fictitious person, or falsely makes, alters, forges, utters,  
publishes, passes, or attempts to pass, as genuine, any prescription for any drugs is guilty of  
forgery.

45. Section 4333 of the Code states, in pertinent part, that all prescriptions filled by a  
pharmacy and all other records required by Section 4081 shall be maintained on the premises and  
available for inspection by authorized officers of the law for a period of at least three years. In  
cases where the pharmacy discontinues business, these records shall be maintained in a



1 board-licensed facility for at least three years.

2 46. Section 111255 of the Health & Safety Code states that any drug or device is  
3 adulterated if it has been produced, prepared, packed, or held under conditions whereby it may  
4 have been contaminated with filth, or whereby it may have been rendered injurious to health.

5 47. Section 111295 of the Health & Safety Code states that it is unlawful for any person  
6 to manufacture, sell, deliver, hold, or offer for sale any drug or device that is adulterated.

7 **REGULATORY PROVISIONS**

8 48. Title 16, section 1711, of the California Code of Regulations states, in pertinent part:

9 (a) Each pharmacy shall establish or participate in an established quality  
10 assurance program which documents and assesses medication errors to determine  
11 cause and an appropriate response as part of a mission to improve the quality of  
12 pharmacy service and prevent errors.

13 ...

14 (c) (1) Each quality assurance program shall be managed in accordance with  
15 written policies and procedures maintained in the pharmacy in an immediately  
16 retrievable form.

17 (2) When a pharmacist determines that a medication error has occurred, a pharmacist  
18 shall as soon as possible:

19 (A) Communicate to the patient or the patient's agent the fact that a medication error  
20 has occurred and the steps required to avoid injury or mitigate the error.

21 (B) Communicate to the prescriber the fact that a medication error has occurred.

22 ...

23 (d) Each pharmacy shall use the findings of its quality assurance program to  
24 develop pharmacy systems and workflow processes designed to prevent medication  
25 errors. An investigation of each medication error shall commence as soon as is  
26 reasonably possible, but no later than 2 business days from the date the medication  
27 error is discovered. All medication errors discovered shall be subject to a quality  
28 assurance review.

(e) The primary purpose of the quality assurance review shall be to advance  
error prevention by analyzing, individually and collectively, investigative and other  
pertinent data collected in response to a medication error to assess the cause and any  
contributing factors such as system or process failures. A record of the quality  
assurance review shall be immediately retrievable in the pharmacy. The record shall  
contain at least the following:

(1) the date, location, and participants in the quality assurance review;

(2) the pertinent data and other information relating to the medication error(s)  
reviewed and documentation of any patient contact required by subdivision (c);



1 (3) the findings and determinations generated by the quality assurance review;  
and,

2 (4) recommend changes to pharmacy policy, procedure, systems, or processes,  
if any.

3 ...

4 (f) The record of the quality assurance review, as provided in subdivision (e)  
5 shall be immediately retrievable in the pharmacy for at least one year from the date  
the record was created.

6 ...

7 49. Title 16, section 1713, of the California Code of Regulations states, in pertinent part:

8 (a) Except as otherwise provided in this Division, no licensee shall participate  
9 in any arrangement or agreement, whereby prescriptions, or prescription medications,  
may be left at, picked up from, accepted by, or delivered to any place not licensed as  
10 a retail pharmacy.

11 ...

12 50. Title 16, section 1716, of the California Code of Regulations states, in pertinent part:

13 Pharmacists shall not deviate from the requirements of a prescription except  
14 upon the prior consent of the prescriber or to select the drug product in accordance  
with Section 4073 of the Business and Professions Code.

15 ...

### 16 **COST RECOVERY**

17 51. Section 125.3 of the Code provides, in pertinent part, that the Board may request the  
18 administrative law judge to direct a licensee found to have committed a violation or violations of  
19 the licensing act to pay a sum not to exceed the reasonable costs of the investigation and  
20 enforcement of the case, with failure of the licensee to comply subjecting the license to not being  
21 renewed or reinstated. If a case settles, recovery of investigation and enforcement costs may be  
22 included in a stipulated settlement.

### 23 **FACTUAL ALLEGATIONS**

24 52. At all times relevant herein, Respondent Alkazaki was the pharmacist-in-charge at  
25 Palm Care and Palm Care National City. At all times relevant herein, Respondent Kala was  
26 employed as a staff pharmacist at Palm Care. At all times relevant herein, Respondent Cortez-  
27 Gomez was employed as a staff pharmacist at Palm Care. The Board's eight investigations  
28 revealed the following facts.

## MOLINA INVESTIGATION

1  
2 53. On or about November 11, 2020, the Board received complaints from Neighborhood  
3 Healthcare (NHC) that primarily concerned Palm Care falsifying multiple *insurance approval*  
4 *requests* and dispensing unauthorized prescriptions that were falsely attributed to providers at  
5 NHC's El Cajon clinic. Palm Care had also falsified insurance approval requests, and dispensed  
6 unauthorized prescriptions, related to non-NHC providers. The falsified insurance approval  
7 requests at issue, whether attributed to providers at NHC or elsewhere, were submitted to Molina  
8 Healthcare (Molina) for approval.

9 54. The high-cost diabetes medication Metformin ER Gastric (brand name Glumetza)  
10 was the subject of the majority of these falsified insurance approval requests. Metformin ER  
11 *Gastric*, a newer drug, may be dispensed in response to gastrointestinal side effects that arise  
12 from use of the original Metformin ER (brand name Glucophage). However, Metformin ER  
13 Gastric is generally more expensive than Metformin ER, at one point during the time of this  
14 investigation ranging approximately \$4 to \$50 per tablet, as billed to insurers by the pharmacy,  
15 while the approximate cost of Metformin ER ranged \$0.05 to \$0.27 per tablet.

16 55. As part of its cost and utilization controls for certain high-cost prescription drugs,  
17 California's public health insurance program Medi-Cal requires that approval be secured from a  
18 patient's private insurer before coverage will apply under the program. The request for the  
19 insurer's approval, known as a *prior authorization* request, occurs on a form that documents for  
20 the insurer why the requested benefit is medically necessary. Prior authorization was required for  
21 Metformin ER Gastric at all times relevant herein, whereas prior authorization was not required  
22 for Metformin ER.

23 56. Molina is one of the private insurers that receives Medi-Cal funds and provides  
24 coverage under the program to the public, and was the insurer that reviewed and approved the  
25 fraudulent prior authorization requests for Metformin ER Gastric at issue in this case. Molina  
26 requires the prescriber to authorize the request, and at the end of the request form has a field for  
27 the prescriber to attest to the truth of the contents of the request by signature or electronic ID  
28 verification. If the requestor completing the form is different from the prescriber authorizing the

1 request, there is a field for the requestor to identify themselves on the first page of the form, in the  
2 same section where the prescriber's identifying information is provided. In addition, there is a  
3 section in the request form where the medical justification for the request must be described.

4 57. Molina performed an audit after it learned Palm Care was submitting prior  
5 authorizations and dispensing prescriptions for Metformin ER Gastric that had not been requested  
6 by the prescribers. Molina's audit of the period between May 17, 2019 to April 29, 2020  
7 determined that an overpayment to Palm Care of \$307,404.94 had occurred under the approval of  
8 41 prior authorization requests, resulting in Metformin ER Gastric being dispensed more than 150  
9 times. Molina notified Palm Care of its findings on or about December 18, 2020. Palm Care  
10 continued to dispense and bill Molina for Metformin ER Gastric beyond the audit period such that  
11 through the first seven months of 2020 Palm Care had dispensed the medication 278 times,  
12 whereas four local comparison pharmacies had each dispensed the medication less than 10 times.

13 58. Palm Care's fraud extended beyond the act, in these 41 instances, of submitting a  
14 prior authorization request without the prescriber's knowledge, for a medication unauthorized by  
15 the prescriber. Rather, the requests themselves contained false statements and were completed in  
16 a deceptive manner. Specifically, these prior authorization requests were completed in a way that  
17 made it appear that it was made by the prescriber. With many of the requests, there was no  
18 indication in the relevant field on the first page of the form that the requestor was different from  
19 the prescriber, while in many other instances a name or part of a name was written without an  
20 indication that the named individual had no affiliation with the prescriber. Similarly, the  
21 signature at the end of the form on the prescriber line failed to give any degree of notice that the  
22 requestor was a pharmacy acting on its own initiative.<sup>3</sup> Moreover the narrative provided on the  
23 form to justify the request furthered the deception, often through a purported summary of the  
24 patient's medical history and purported adverse reactions to regular Metformin, with further false  
25 and deceptive statements such as, "Doctor recommends to start new therapy with Metformin Er  
26 500mg gastric," "Doctor switched him to Glumetza," and "Must stop Metformin & start

27 \_\_\_\_\_  
28 <sup>3</sup> On 37 of the 41 forms the signature was not legible, on one the signature line was left blank, and  
the three legible signatures did not otherwise identify the signer.

1 Glumetza.”

2 59. The findings of Molina’s audit were validated during the Board’s investigation with a  
3 sampling of 12 of the original 41 prior authorization requests. The clinic and/or prescriber in  
4 those instances again confirmed that Metformin ER Gastric was unauthorized. Specifically, two  
5 NHC providers, Dr. N.J., and Dr. K.M., accounting for 5 of the 41 prior authorization patient  
6 requests, directly confirmed that they had neither authorized the Metformin ER Gastric  
7 prescriptions attributed to them by Palm Care, nor had authorized or made a prior authorization  
8 request in support of them. A third NHC provider, Dr. J.T., no longer worked at NHC at the time  
9 of the investigation, but her patient records did not include an authorization for Metformin ER  
10 Gastric for the patient at issue who was formerly under her care at NHC. A fourth NHC provider,  
11 Dr. J.H., had passed away, but his patient records did not include an authorization for Metformin  
12 ER Gastric for the patient at issue who was formerly under his care at NHC. Two non-NHC  
13 providers, unaffiliated with one another, Dr. F.J. and Dr. M.B., accounting for another 5 of the 41  
14 prior authorization patient requests, similarly confirmed that they had neither authorized the  
15 Metformin ER Gastric prescriptions attributed to them by Palm Care, nor had made a prior  
16 authorization request in support of them. From this grouping of prior authorization patient  
17 requests, the corresponding unauthorized Metformin ER Gastric prescriptions dispensed to three  
18 of Dr. F.J.’s patients were dispensed by Respondent Cortez-Gomez under Rx # 321107, Rx #  
19 281475, and Rx # 278600.

20 60. In 2022, while the Molina audit were being validated, Palm Care continued to  
21 dispense unauthorized Metformin ER Gastric, as evidenced by the contents of faxed refill request  
22 forms sent to Dr. F.J. showing that the unauthorized medication had recently been dispensed.  
23 Palm Care continued to fax such prescription refill requests for Metformin ER Gastric to Dr. F.J.  
24 even after she had expressly denied earlier refill requests for the drug and informed Palm Care  
25 that she would not authorize it in the future.

26 61. Patients were also seemingly being coached to report abdominal discomfort in order  
27 to justify the more expensive Metformin ER Gastric. After years of care having not mentioned  
28 adverse reactions to their medications, some of Dr. F.J.’s patient on Metformin ER were suddenly

1 mentioning abdominal pain. When she asked these patients clarifying questions, they were  
2 unable to further describe the nature of the complications they were reporting. This lead Dr. F.J.  
3 to suspect the patients were being coached to report abdominal pain. Similarly, in 2020, *after*  
4 NHC learned of an unauthorized prior authorization submittal for a patient of Dr. N.J., and  
5 notified Palm Care that only regular Metformin ER was authorized for that patient, the patient  
6 contacted NHC to inform the clinic that she was requesting the change to Metformin ER Gastric.

7       62. Palm Care was also using the National Provider Identifier (NPI) and Drug  
8 Enforcement Administration (DEA) number of an NHC provider, Nurse Practitioner S.C., to  
9 submit prescription billings to insurers without the provider's knowledge or authorization. NPI  
10 numbers are unique identifiers issued by the Centers for Medicare and Medicaid Services to  
11 health care providers, and are used in electronic health care transactions and communications,  
12 including on prescription billings. Insurers generally will not process a claim without an  
13 appropriate NPI number associated with the claim. DEA numbers are unique identifiers issued by  
14 the Drug Enforcement Administration to allow providers to write controlled substance  
15 prescriptions, which the DEA can then monitor. Respondent Alkazaki used the identifiers  
16 assigned to NHC Nurse Practitioner S.C. on approximately 282 prescriptions between January 1,  
17 2020 and December 9, 2020. Approximately 24 of these prescriptions were recorded as having  
18 been cancelled, leaving the remaining 258 as completed and billed to a variety of insurers  
19 including Molina and Community Health.

20       63. Apart from the falsified Metformin ER Gastric prior authorizations, Palm Care  
21 falsified a prior authorization for a Tretinoin prescription issued by NHC provider Dr. S.S. In this  
22 instance the prescription itself was authorized, but the provider was not aware that Palm Care had  
23 submitted a prior authorization request, and the request generated by Palm Care justified the prior  
24 authorization request by falsely reporting to Molina that the patient had previously tried an  
25 alternate medication. Respondent Cortez-Gomez also dispensed three other unauthorized  
26 prescriptions to the patient of NHC provider Dr. J.T. under Rx # 306678, Rx # 285437, and Rx #  
27 285438.

28 ///

1 **QLARANT INVESTIGATION**

2 64. On or about September 26, 2022, the Board received notification from Qlarant, a  
3 Medicare Integrity Program contractor, reporting substantial inventory shortages at Palm Care  
4 National City based on invoice and billing review. As a result, the pharmacy’s purchases and  
5 sales of Metformin ER Gastric 500 mg were audited. The audit confirmed the pharmacy had  
6 fraudulently billed insurers for tens of thousands more tablets than the pharmacy had itself  
7 purchased in a 13-month audit period from January 1, 2020 to January 31, 2021.

8 65. Among the records furnished by Palm Care National City during the Board’s  
9 investigation was the pharmacy’s internally maintained *dispensing data*, an audit record that  
10 purported to give the amount of Metformin ER Gastric tablets the pharmacy had purchased and  
11 dispensed, and acquisition data that purported to give detailed information on the pharmacy’s  
12 Metformin ER Gastric purchases. The pharmacy fabricated the contents of the audit record and  
13 acquisition data to conceal a purchase to sales shortage of more than 50,000 tablets.

14 66. Palm Care National City’s *dispensing data* recorded that the pharmacy had dispensed  
15 and billed 135,870 Metformin ER Gastric 500 mg tablets under three National Drug Codes  
16 (NDCs) in the audit period, equaling more than \$9 million in sales and \$6.5 million in gross  
17 profits when applying the pharmacy’s reported average total price submitted of approximately  
18 \$66.84 per tablet and average total price paid of approximately \$17.62 per tablet.<sup>4</sup>

19 67. Palm Care National City’s audit records and acquisition data reported the pharmacy  
20 had purchased 150,100 Metformin ER Gastric 500 mg tablets, and gave the same 135,870 sales  
21 total recorded in the pharmacy’s *dispensing data*. The pharmacy thus represented that purchases  
22 exceeded sales by 14,230 tablets.<sup>5</sup> However, the audit records also reported a significant excess  
23 of the drug under the NDC for the manufacturer Lupin Pharmaceuticals, and a significant  
24 shortage of the drug under the NDC for the manufacturer Northstar Rx LLC, as follows:

25 ///

26 \_\_\_\_\_  
27 <sup>4</sup> A NDC is a unique identifier under which a drug intended for human use is registered with the  
28 FDA. A NDC will vary by manufacturer, even for the same drug, as well as by product.

<sup>5</sup> The pharmacy would also presumably have some inventory on hand at the start of the audit  
period. During a December 21, 2022 inspection of the pharmacy, 7,300 tablets were in inventory.

NDC	Purchased	Dispensed	Difference
68180033801 (Lupin Pharmaceuticals)	54,400	10,470	43,930
16714093801 (Northstar Rx LLC)	2,200	48,120	(45,920)
68682002150 (Valeant Pharmaceuticals)	93,500	77,280	16,220
<b>Totals</b>	<b>150,100</b>	<b>135,870</b>	<b>14,230</b>

68. Given the records furnished by Palm Care National City, many Metformin ER Gastric tablets manufactured by Lupin Pharmaceuticals were dispensed (and billed) under a label that described the tablet as manufactured by Northstar Rx LLC. By dispensing Metformin ER Gastric tablets from one manufacturer under a label inscribed with the color, shape, or identification code for the tablet produced by another manufacturer, the pharmacy would necessarily be incorrectly labeling the dispensed prescription. This labeling violation is not inherently dangerous, but may produce confusion that leads to patient harm.<sup>6</sup> A pharmacy may also slightly increase its profits by fraudulently billing a prescription under a substituted NDC.<sup>7</sup>

69. Palm Care National City’s acquisition records reported Metformin ER Gastric 500 mg purchases from four different wholesalers, including the false report of 54,400 tablets purchased under NDC 68180033801 (manufactured by Lupin Pharmaceuticals) from wholesaler MTS Health Supplies. The acquisition records furnished by the pharmacy reported the acquisition of the 54,400 tablets over 37 transactions, each under a unique “invoice number.” As of January 11, 2023, MTS Health Supplies had never sold Metformin ER Gastric to Palm Care National City under any of the Metformin Gastric NDCs the pharmacy claimed to have acquired. MTS further confirmed that the 37 invoice numbers did not belong to them. Palm Care National City also failed to furnish copies of any of the 37 invoices for these purported MTS transactions as requested on July 18, 2023 and again on July 31, 2023. Inquiries were sent to other wholesalers, none of whom verified the purchases attributed by the pharmacy to MTS.

<sup>6</sup> For instance, a patient who noticed that the tablet did not match the label’s description may believe they received the wrong medication and deviate from their prescribed medication schedule.

<sup>7</sup> Here for instance, Palm Care National City’s *gross profit* on sales under the Valeant Pharmaceuticals NDC is over 4% greater than on sales under the Lupin Pharmaceuticals NDC. That differential would rise instead to over 7% by falsely billing a Valeant sale as a Lupin sale.



1           70. Palm Care National City also reported the purchase of 93,500 tablets under NDC  
2 68682002150 (Valeant Pharmaceuticals) which was verified with the two wholesales indicated by  
3 the pharmacy. Only 1,700 of the 2,200 reported tablets purchased under NDC 16714093801  
4 (Northstar Rx LLC), coming from a third wholesaler, were verified. The remaining 500 tablets  
5 had been returned by the pharmacy to the seller.

6           71. Reducing the pharmacy's reported 150,100 tablet purchases by the falsified 54,400  
7 purchase report, and the additional 500 tablets returned, leaves an acquisition total of 95,200  
8 tablets in the audit period. The difference between the 135,870 tablets dispensed and billed and  
9 the true acquisition total of 95,200 leaves a 40,670 tablet inventory shortage; a shortage  
10 equivalent to 42.72% of all acquisitions in the 13-month audit period, 29.93% of all sales, or  
11 more than \$700,000 in inventory.

12 ///

13 ///

14 ///

15 ///

16 ///

17 ///

18 ///

19 ///

20 ///

21 ///

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///



1 **LATUDA INVESTIGATION**

2 72. On or about April 27, 2023, a Board inspection of Palm Care was performed to gather  
3 information for an audit of the pharmacy’s purchases and sales of the high-cost medication  
4 Lurasidone (brand name Latuda). Latuda averaged approximately \$69.21 per tablet, as billed by  
5 the pharmacy to insurers. The audit confirmed the pharmacy had fraudulently billed insurers for  
6 tens of thousands more tablets than the pharmacy had itself purchased in a 3-year audit period  
7 from April 27, 2020 to April 27, 2023.

8 73. Palm Care’s internally maintained *dispensing data* recorded that the pharmacy had  
9 dispensed and billed 40,025 Latuda tablets of various strengths in the audit period, equaling more  
10 than \$2.75 million in sales and \$900,000 in gross profits when applying the pharmacy’s reported  
11 average total price submitted of approximately \$69.21 per tablet and average total price paid of  
12 approximately \$46.16 per tablet.

13 74. Inquiries were sent to drug wholesalers to determine Palm Care’s Latuda acquisition  
14 totals.<sup>8</sup> Over the 3-year audit period, the pharmacy acquired 20,370 Latuda tablets of various  
15 strengths while dispensing and billing for sales of 40,025 tablets. These totals leave a 19,655  
16 tablet inventory shortage; a shortage equivalent to 96.48% of all acquisitions in the audit period,  
17 49.1% of all sales, or more than \$900,000 in inventory when applying the pharmacy’s reported  
18 average total price paid of approximately \$46.16 per tablet.<sup>9</sup> At the time of the Board’s  
19 inspection of the pharmacy on April 27, 2023, Respondent Alkazaki said that although the  
20 pharmacy dispensed a large amount of Latuda, the pharmacy did not keep large amounts of it in  
21 inventory because of its cost. A more detailed breakdown of the pharmacy’s acquisitions and  
22 sales in the audit period for the various strengths of the drug is as follows:

23 ///

24 ///

25 ///

26 <sup>8</sup> Palm Care did not provide its own audit records or acquisition data despite requests made to the  
27 pharmacy by the Board’s investigator in July 2023 and again in February 2024.

28 <sup>9</sup> The pharmacy would also presumably have some inventory on hand at the start of the audit  
period. On April 27, 2023, only 12 tablets were in inventory at the pharmacy, all of which were  
20 mg tablets, and thus equaling approximately \$500 in inventory.

<i>April 27, 2020 to October 26, 2020</i>	<b>Purchased</b>	<b>Dispensed</b>	<b>Difference</b>	<i>Rolling Total</i>
Latuda 20 mg	-30	900	-930	<b>-930</b>
Latuda 40 mg	1,200	3,510	-2,310	<b>-2,310</b>
Latuda 60 mg	450	1,800	-1,350	<b>-1,350</b>
Latuda 80 mg	1,320	4,470	-3,150	<b>-3,150</b>
Latuda 120 mg	270	1,260	-990	<b>-990</b>
<b>Totals (183 days)</b>	<b>3,210</b>	<b>11,940</b>	<b>-8,730</b>	<b>-8,730</b>

<i>October 27, 2020 to April 26, 2021</i>	<b>Purchased</b>	<b>Dispensed</b>	<b>Difference</b>	<i>Rolling Total</i>
Latuda 20 mg	300	120	180	<b>-750</b>
Latuda 40 mg	750	1,770	-1,020	<b>-3,330</b>
Latuda 60 mg	150	30	120	<b>-1,230</b>
Latuda 80 mg	1230	360	870	<b>-2,280</b>
Latuda 120 mg	270	690	-420	<b>-1,410</b>
<b>Totals (182 days)</b>	<b>2,700</b>	<b>2,970</b>	<b>-270</b>	<b>-9,000</b>

<i>April 27, 2021 to October 26, 2021</i>	<b>Purchased</b>	<b>Dispensed</b>	<b>Difference</b>	<i>Rolling Total</i>
Latuda 20 mg	270	62	208	<b>-542</b>
Latuda 40 mg	720	247	473	<b>-2,857</b>
Latuda 60 mg	660	150	510	<b>-720</b>
Latuda 80 mg	1,500	0	1,500	<b>-780</b>
Latuda 120 mg	360	360	0	<b>-1,410</b>
<b>Totals (183 days)</b>	<b>3,510</b>	<b>819</b>	<b>2,691</b>	<b>-6,309</b>

<i>October 27, 2021 to April 26, 2022</i>	<b>Purchased</b>	<b>Dispensed</b>	<b>Difference</b>	<i>Rolling Total</i>
Latuda 20 mg	420	478	-58	<b>-600</b>
Latuda 40 mg	1,200	1,140	60	<b>-2,797</b>
Latuda 60 mg	690	660	30	<b>-690</b>
Latuda 80 mg	540	900	-360	<b>-1,140</b>
Latuda 120 mg	420	630	-210	<b>-1,620</b>
<b>Totals (182 days)</b>	<b>3,270</b>	<b>3,808</b>	<b>-538</b>	<b>-6,847</b>

<i>April 27, 2022 to October 26, 2022</i>	<b>Purchased</b>	<b>Dispensed</b>	<b>Difference</b>	<b>Rolling Total</b>
Latuda 20 mg	690	1,093	-403	<b>-1,003</b>
Latuda 40 mg	1,290	1,860	-570	<b>-3,367</b>
Latuda 60 mg	1,380	3,315	-1,935	<b>-2,625</b>
Latuda 80 mg	810	3,930	-3,120	<b>-4,260</b>
Latuda 120 mg	150	540	-390	<b>-2,010</b>
<b>Totals (183 days)</b>	<b>4,320</b>	<b>10,738</b>	<b>-6,418</b>	<b>-13,265</b>

<i>October 27, 2022 to April 27, 2023</i>	<b>Purchased</b>	<b>Dispensed</b>	<b>Difference</b>	<b>Rolling Total</b>
Latuda 20 mg	180	450	-270	<b>-1,273</b>
Latuda 40 mg	1,110	1,680	-570	<b>-3,937</b>
Latuda 60 mg	1,290	2,910	-1,620	<b>-4,245</b>
Latuda 80 mg	630	4,110	-3,480	<b>-7,740</b>
Latuda 120 mg	150	600	-450	<b>-2,460</b>
<b>Totals (183 days)</b>	<b>3,360</b>	<b>9,750</b>	<b>-6,390</b>	<b>-19,655</b>

<i>April 27, 2020 to April 27, 2023</i>	<b>Purchased</b>	<b>Dispensed</b>	<b>Difference</b>
Latuda 20 mg	1,830	3,103	-1,273
Latuda 40 mg	6,270	10,207	-3,937
Latuda 60 mg	4,620	8,865	-4,245
Latuda 80 mg	6,030	13,770	-7,740
Latuda 120 mg	1,620	4,080	-2,460
<b>Totals (1,096 days)</b>	<b>20,370</b>	<b>40,025</b>	<b>-19,655</b>

///

///

///

///

///

///

///

## LA MAESTRA INVESTIGATION

75. Beginning on or about April 17, 2018, the Board received a series of complaints from La Maestra Community Health Center in El Cajon (La Maestra) about prescriptions filled at Palm Care being falsely reported as authorized by providers at La Maestra. Palm Care billed such false prescriptions to insurers, including Molina, Aetna PDP, and Community Health Group.

76. Palm Care sent repeated prescription authorization requests on printed forms to La Maestra, but then dispensed the prescription without the prescriber's authorization. In some instances, Palm Care continued to dispense medication even after La Maestra notified Palm Care it was dispensing an unauthorized prescription. La Maestra reported that these prescriptions were for medications which had either never been authorized, or had once been authorized for the patient, but the more recent refills had not been authorized. Frequently, as of August 2018, the patient who was the subject of the false prescription, had not even been seen as a patient at La Maestra for years. Palm Care falsely authorized prescriptions for at least six patients: M.K., S.S., C.B., I.M., I.S., and K.B.

77. La Maestra provided 12 of the printed request refill authorization forms it had received from Palm Care for these six patients. These refill requests were directed to La Maestra providers Dr. R.M. and Dr. W.R. Each form contains preprinted information, which includes what purports to be the most recent dispensing history for the prescription, a unique Rx # for the last authorization, the name of the prescriber that is the target of the request, and the date of the request. A space is available for the authorizing prescriber to date, indicate the number of refills authorized, if any, and sign above their pre-printed name. A new unique Rx # would be generated after a (purported) new prescription authorization was received. Thus, the Rx # preprinted on the request refill form would relate only to the most recent prior prescription authorization that had already been dispensed.

78. Respondent Alkazaki was asked to provide hard copies of the prescriber authorizations for these 12 false prescriptions, and in response he produced 12 of the pharmacy's request refill authorization forms. Eight of the 12 forms provided purported to reflect that refill authorization had been given by phone. The remaining four request refill authorization forms, i.e.

1 under Rx # 129545, Rx # 126233, and Rx # 136394 for patient K.B., and Rx # 79471 for patient  
2 M.K., appeared less like a record of a purported phone authorization, but instead had an apparent  
3 check mark on the signature line in two instances, and a wavy line in the other two.

4 79. Of the 12 printed request refill authorization forms Respondent Alkazaki provided, 6  
5 had a “Rx #” which matched the number shown on the version of the form provided by La  
6 Maestra, while 6 had a non-matching Rx #, but matched the relevant patient and medication.  
7 Thus in the comparisons of the contents of the different versions of the forms which is given in  
8 paragraphs 84 through 89, below, different Rx #s sometimes appear.

9 80. In addition, despite that Palm Care had sent all 12 authorization requests to La  
10 Maestra, Palm Care’s records ultimately attributed prescriber authorization for 4 of these 6  
11 request refill authorization forms with a non-matching Rx # to the following providers who were  
12 not associated with La Maestra: Dr. L. R., Dr. H.A., and Dr. M.B. However, Dr. L. R. confirmed  
13 that the prescription authorizations referenced above and attributed to her within Palm Care’s  
14 records for patients I.M. and I.S., were false. Dr. C.C. confirmed that based on a chart review, the  
15 prescription authorizations described above and attributed to Dr. H.A. at Family Health Centers  
16 of San Diego for patient K.B. were false.

17 81. Aside from the confirmation given by the various prescribers that the prescriptions  
18 attributed to them were unauthorized, a wide variety of discrepancies in Palm Care’s records  
19 across three different sources confirmed that its dispensing records were altered. Namely, there  
20 are multiple discrepancies among (a) the dispensing history reported on the version of the request  
21 refill forms maintained by Palm Care, (b) the dispensing history reported on the version of the  
22 request refill forms sent to the La Maestra providers by Palm Care, and (c) Palm Care’s internally  
23 maintained *dispensing data*, a record of all the pharmacy’s dispensing activities, produced by  
24 Palm Care during the investigation in spreadsheet format. The content of these often inconsistent  
25 records are presented in paragraphs 84 through 89, below. These discrepancies, which reveal that  
26 dispensing records were altered, further confirm the fraudulent nature of the 12 prescriptions.

27 ///

28 ///

1           82. **Patients X and S.O.** Palm Care committed a dispensing error involving a patient  
2 S.O. The patient contacted Palm Care to report the error, and in response, a delivery driver had  
3 retrieved the drug, levothyroxine, to return it to the pharmacy. A copy of the prescription label  
4 and accompanying register receipt from this error, which S.O. initially provided to Dr. R.M.,  
5 showed S.O.'s name under prescription number 157230 for 30 tablets with another 60 on the  
6 prescription. Respondent Alkazaki's initials were on the label. The label and register receipt  
7 were dated 6/26/18. However, Palm Care's dispensing data did not reflect that levothyroxine was  
8 dispensed to S.O. Rather the dispensing data recorded that prescription number 157230 was  
9 filled on August 15, 2018 for a different patient, who will be referred to here as Patient X.<sup>10</sup> The  
10 dispensing data had therefore been altered by Palm Care to omit the June 2018 dispensing error.

11           83. Palm Care's dispensing records for Patient X's prescription for levothyroxine reflect  
12 further record discrepancies, including a pattern of excessive furnishing of dangerous drugs in  
13 relation to the use rate purportedly authorized by the prescriber. This pattern of excessive  
14 furnishing of drugs in relation to the use rate purportedly authorized is found to varying degrees  
15 within the records applicable to other patients, and is presented through the dispensing history for  
16 those patients which appear in paragraphs 84 through 89, below. A summary of Patient X's  
17 dispensing history for levothyroxine is presented here, as follows:

18           a) Palm Care's dispensing data records show that Patient X was prescribed  
19 levothyroxine on October 24, 2016. Patient X was instructed to "take one tablet by mouth every  
20 day thyroid," but was issued 90 tablets as a 30-day supply. The fifth 90 tablet refill was filled on  
21 March 28, 2017, thus totaling 540 tablets dispensed in this 155 day period.

22           b) Palm Care's dispensing data records show that Patient X was again given the  
23 same prescription on February 27, 2017, before the date of the final refill given on the previous  
24 prescription. The February 27, 2017 prescription was first filled on April 23, 2017, and the fifth  
25 90 tablet refill was filled 133 days later on September 3, 2017, which would accordingly total 540  
26 tablets dispensed. Adding 30 days of use to this 133-day time span would result in Patient X  
27 receiving 3.31 tablets per day in this period while being instructed to take one tablet daily.

28 <sup>10</sup> This patient's actual initials are identical to another patient's initials already used above.

1 c) Palm Care's dispensing data records show that Patient X was again given the  
2 same prescription on May 18, 2017, which would have overlapped with the period of the previous  
3 5 refills. The May 18, 2017 prescription was first filled on October 1, 2017, giving Patient X 90  
4 tablets only 28 days since the last issuance of 90 tablets. The eighth 90 tablet refill was filled 212  
5 days later on May 1, 2018, which would total 810 tablets dispensed. Adding 30 days to this 212-  
6 day time span would result in Patient X receiving 3.34 tablets per day in this period while still  
7 being instructed to take one tablet daily.

8 d) Palm Care's dispensing data records show that Patient X was again given the  
9 same prescription on May 28, 2018, on which date the prescription was first filled, giving Patient  
10 X 90 tablets only 27 days since the last issuance of 90 tablets. The second 90 tablet refill was  
11 filled 53 days later on July 20, 2018, which would total 270 tablets dispensed. Adding 30 days to  
12 this 53-day time span would result in Patient X receiving 3.25 tablets per day in this period.

13 e) Palm Care's dispensing data records show that Patient X was again  
14 prescribed levothyroxine on June 26, 2018. Patient X was still instructed to take one tablet daily,  
15 but this time was issued 30 tablets as a 30-day supply beginning August 15, 2018 under  
16 prescription number 157230. The sixth 30 tablet refill was filled 162 days later on January 24,  
17 2019, which would total 210 tablets dispensed. Adding 30 days to this 162-day time span would  
18 result in Patient X receiving 1.09 tablets per day in this period.

19 f) In the course of the Board's investigation, Respondent Alkazaki was asked to  
20 provide the original prescription for Rx # 157230, as this was the number on the prescription label  
21 received by S.O., with S.O.'s name on the label. Respondent Alkazaki provided a printed copy of  
22 an electronic prescription for Patient X bearing Rx # 150186, accompanied by a backtag sticker  
23 for prescription number 157230. Rx # 150186 was recorded in Palm Care's dispensing data as  
24 the May 28, 2018 prescription to Patient X. The backtag sticker bearing number 157230 was  
25 recorded in Palm Care's dispensing data as the June 26, 2018 prescription also for Patient X,  
26 delivered on August 15, 2018. This June 26, 2018 electronic prescription authorized 90 tablets as  
27 a 30-day supply, without authorization for refills, and instructed the use of one tablet daily. As  
28 indicated above, Palm Care's dispensing data records the issuance of 30 tablets as a 30 day supply

1 under Rx # 157230 beginning August 15, 2018, but with 6 refills subsequently dispensed. The  
2 210 tablets dispensed would thus be in excess of the quantity authorized on the face of the  
3 prescription. The label that had been delivered to S.O. under Rx # 157230 on June 26, 2018 had  
4 been for 30 tablets with another 60 on the prescription, which is likely the quantity intended by  
5 the June 26, 2018 electronic prescription for Patient X provided by Respondent Alkazaki given  
6 the “one tablet daily” instruction.

7 84. **Patient M.K.** Of the 12 false prescriptions identified by La Maestra, one was for  
8 M.K. As of August of 2018, M.K. had last been seen at La Maestra on October 19, 2015. Palm  
9 Care produced two refill request forms for the same medication, under Rx # 86267 and Rx #  
10 79471.

11 a) **Oyster Shell Calcium.** Rx # 86267 and Rx # 79471 were for Oyster Shell  
12 Calcium 500 mg, recorded as initially dispensed by Respondent Alkazaki, with multiple refills  
13 dispensed by Respondent Kala under Rx # 86267. As of August of 2018, La Maestra had last  
14 authorized this medication for M.K. on October 5, 2015, at which time 5 refills were authorized.  
15 The request form *obtained from Palm Care* during the Board investigation of the false  
16 prescription for Rx # 79471 indicated as follows:

17 ///

18 ///

19 ///

20 ///

21 ///

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
8/30/17	8/30/17	60	6	
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
8/2/17	8/2/17	60	0	1

The request form *obtained from Palm Care* during the Board investigation of the false prescription for Rx # 86267 indicated as follows:

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
3/13/18	3/13/18	60	6	
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Dispensed
8/30/17	2/11/18	420	6	7

The prescription history information in the form *obtained from La Maestra*, which accordingly lacked an indication the request was approved, was for Rx # 86267 and indicated as follows:

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
4/9/18		60		
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
8/30/17	4/9/18	480	8	8

The prescription history information contained in Palm Care’s *dispensing data* for this medication indicated as follows<sup>11</sup>:

///

<sup>11</sup> Rx Numbers which appear with an asterisk in this table, and corresponding tables below unless otherwise indicated, mark a prescription authorization not attributed to a provider at La Maestra as recorded in Palm Care’s dispensing data.

Rx Num.	Date Written	Date Filled	Quantity	Refill Num.	Days Supply
207503*	2/5/2019	2/5/2019	60	0	30
130269	3/13/2018	10/12/2018	60	6	30
130269	3/13/2018	9/15/2018	60	5	30
130269	3/13/2018	8/20/2018	60	4	30
130269	3/13/2018	7/24/2018	60	3	30
130269	3/13/2018	6/27/2018	60	2	30
130269	3/13/2018	6/1/2018	60	1	30
130269	3/13/2018	5/6/2018	60	0	30
139512		4/17/2018	[Cancelled]		
86267	8/30/2017	4/9/2018	60	8	30
86267	8/30/2017	3/13/2018	60	7	30
86267	8/30/2017	2/11/2018	60	6	30
86267	8/30/2017	1/15/2018	60	5	30
86267	8/30/2017	12/19/2017	60	4	30
86267	8/30/2017	11/22/2017	60	3	30
86267	8/30/2017	10/25/2017	60	2	30
86267	8/30/2017	9/27/2017	60	1	30
86267	8/30/2017	8/30/2017	60	0	30
79471	8/2/2017	8/2/2017	60	0	30
45048	1/27/2017	7/5/2017	60	6	30
45048	1/27/2017	6/8/2017	60	5	30
45048	1/27/2017	5/13/2017	60	4	30
45048	1/27/2017	4/17/2017	60	3	30
45048	1/27/2017	3/21/2017	60	2	30
45048	1/27/2017	2/22/2017	60	1	30

///

///

///

///

1                   b) **Additional Prescriptions.**<sup>12</sup> Additional prescriptions documented in Palm  
 2 Care’s dispensing data for M.K. and attributed to a provider at La Maestra in 2016 and 2017,  
 3 despite the fact that M.K. had last been seen at La Maestra on October 19, 2015, were for Vitamin  
 4 D 2,000 Unit, Lisinopril, and Hm Vitamin D3.

5           85. **Patient S.S.** From the 12 false prescriptions identified by La Maestra, one was for  
 6 S.S. As of August of 2018, S.S. had last been seen at La Maestra on January 31, 2017. The Palm  
 7 Care refill request form was for Rx # 115685:

8                   a) **Simvastatin.** Rx # 115685 was for Simvastatin 20 mg recorded as initially  
 9 dispensed by Respondent Kala, with a refill dispensed by Respondent Alkazaki. La Maestra had  
 10 last authorized this medication for S.S. on January 31, 2017 The request form *obtained from*  
 11 *Palm Care* during the Board investigation of the false prescription indicated as follows:

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
5/31/18	5/31/18	30	2	
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
1/10/18	5/5/18	90	2	3

18 The prescription history information in the form *obtained from La Maestra*, which accordingly  
 19 lacked an indication the request was approved, indicated as follows:

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
4/8/18		30		
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
1/10/18	4/8/18	30	2	1

26  
 27 ///

28 <sup>12</sup> No request forms for these medications were secured during the Board’s investigation.

1 The prescription history information contained in Palm Care's *dispensing data* for this medication  
2 indicated as follows:

Rx Num.	Date Written	Date Filled	Quantity	Refill Num.	Days Supply
151316	5/31/2018	9/16/2018	30	4	30
151316	5/31/2018	8/20/2018	30	3	30
151316	5/31/2018	7/24/2018	30	2	30
151316	5/31/2018	6/27/2018	30	1	30
151316	5/31/2018	5/31/2018	30	0	30
115685	1/10/2018	5/5/2018	30	2	30
115685	1/10/2018	4/8/2018	30	1	30
115685	1/10/2018	3/12/2018	30	0	30
71074	6/19/2017	1/10/2018	30	4	30
71074	6/19/2017	12/19/2017	30	3	30
71074	6/19/2017	8/9/2017	30	2	30
71074	6/19/2017	7/13/2017	30	1	30
71074	6/19/2017	6/19/2017	30	0	30
45452	1/31/2017	5/1/2017	30	3	30
45452	1/31/2017	4/3/2017	30	2	30
45452	1/31/2017	3/7/2017	30	1	30
45452	1/31/2017	1/31/2017	30	0	30

20 86. **Patient C.B.** From the 12 false prescriptions identified by La Maestra, one was for  
21 C.B. As of August of 2018, C.B. had last been seen at La Maestra on October 7, 2016. The Palm  
22 Care refill request form was for Rx # 30574:

23 a) **Levothyroxine.** Rx # 30574 was for Levothyroxine 50 Mcg recorded as  
24 initially dispensed by Respondent Kala, with a refill dispensed by Respondent Alkazaki. La  
25 Maestra had last authorized this medication for C.B. on May 20, 2017, at which time no refills  
26 were authorized. The request form *obtained from Palm Care* during the Board investigation of  
27 the false prescription indicated as follows:

28 ///

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
10/12/17	10/12/12	30	6	
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
9/28/16	9/12/17	90	4	3

The prescription history information in the form *obtained from La Maestra*, which accordingly lacked an indication the request was approved, was for Rx # 96416 and indicated as follows:

Authorization/Request				
Date of Rqst	Date Appr.	Quantity	Refill Auth.	
4/19/18		30		
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
10/12/17	4/19/18	180	6	6

The prescription history information contained in Palm Care's *dispensing data* for this medication indicated as follows:

Rx Num.	Date Written	Date Filled	Quantity	Refill Num.	Days Supply
224608*	4/22/2019	6/4/2019	30	0	30
168581	8/13/2018	11/18/2018	30	3	30
168581	8/13/2018	10/22/2018	30	2	30
168581	8/13/2018	9/26/2018	30	1	30
168581	8/13/2018	8/31/2018	30	0	30
98515	10/21/2017	8/4/2018	30	3	30
98515	10/21/2017	7/9/2018	30	2	30
98515	10/21/2017	6/12/2018	30	1	30
98515	10/21/2017	5/16/2018	30	0	30
96416	10/12/2017	4/19/2018	30	6	30
96416	10/12/2017	3/23/2018	30	5	30
96416	10/12/2017	2/25/2018	30	4	30

1	96416	10/12/2017	1/30/2018	30	3	30
2	96416	10/12/2017	1/4/2018	30	2	30
3	96416	10/12/2017	12/5/2017	30	1	30
4	96416	10/12/2017	11/7/2017	30	0	30
5	65023	5/20/2017	10/12/2017	30	1	30
6	30574*	9/28/2016	9/12/2017	30	2	30
7	30574*	9/28/2016	8/10/2017	30	1	30
8	30574*	9/28/2016	7/12/2017	30	0	30
9	65023	5/20/2017	6/15/2017	30	0	30
10	64477	5/18/2017	5/18/2017	30	0	30
11	30476	9/27/2016	4/18/2017	30	6	30
12	30476	9/27/2016	3/14/2017	30	5	30
	30476	9/27/2016	2/13/2017	30	4	30

13                   b) **Additional Prescriptions.**<sup>13</sup> Additional prescriptions documented in Palm  
14 care’s dispensing data for C.B. and attributed to a provider at La Maestra for 2017 and 2018,  
15 despite the fact that C.B. had last been seen at La Maestra on October 7, 2016, were for Vitamin  
16 D 2,000 Unit, Vitamin D2 1.25 mg, Verapamil Er 180 mg, Ventolin Hfa 90 Mcg, Tudorza  
17 Pressair 400 mcg, Pravastatin Sodium 40 mg, Omeprazole Dr 20 mg, Metoprolol Succ Er 50 mg,  
18 Gabapentin 300 mg, Calcitrate 200 mg, Atenolol 50 mg, and Aspirin Ec 81 mg.

19                   87. **Patient I.M.** Of the 12 false prescriptions identified by La Maestra, 1 was for I.M.  
20 As of August of 2018, I.M. had last been seen at La Maestra on February 27, 2018. The Palm  
21 Care refill request form was for Rx # 118481:

22                   a) **Trifluoperazine.** Rx # 118481 was for Trifluoperazine 1 mg recorded as  
23 initially dispensed by Respondent Alkazaki, with a refill dispensed by Respondent Kala. La  
24 Maestra had last authorized this medication for I.M. on December 7, 2016, at which time 2 refills  
25 were authorized. The request form *obtained from Palm Care* during the Board investigation of  
26 the false prescription indicated as follows:

27 ///

28 <sup>13</sup> No request forms for these medications were secured during the Board’s investigation.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
5/10/18	5/10/18	60	0	
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
1/23/18	2/18/18	120	1	2

The prescription history information in the form *obtained from La Maestra*, which accordingly lacked an indication the request was approved, indicated as follows:

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	Date of Request
4/11/18		60		
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
1/23/18	2/18/18	120	1	2

The prescription history information contained in Palm Care's *dispensing data* for this medication indicated as follows:

Rx Num.	Date Written	Date Filled	Quantity	Refill Num.	Days Supply
191695	11/20/2018	1/7/2019	30	0	30
146011	5/10/2018	5/10/2018	60	3	30
138141		4/11/2018	[Cancelled]		
138133		4/11/2018	[Cancelled]		
118481	1/23/2018	2/18/2018	60	0	30
118481	1/23/2018	1/23/2018	60	3	30
107599	12/2/2017	12/26/2017	60	2	30
107599	12/2/2017	12/2/2017	60	1	30
101563	11/3/2017	11/3/2017	60	0	30
54599	3/28/2017	9/9/2017	60	6	30
54599	3/28/2017	8/11/2017	60	5	30
54599	3/28/2017	7/19/2017	60	4	30

54599	3/28/2017	6/19/2017	60	3	30
54599	3/28/2017	5/23/2017	60	2	30
54599	3/28/2017	4/25/2017	60	1	30
54599	3/28/2017	3/28/2017	60	0	30
38344	12/7/2016	2/28/2017	60	1	30
38344	12/7/2016	2/1/2017	60	2	30
191598	11/20/2018	11/20/2018	60	1	30

b) **Additional Prescriptions.**<sup>14</sup> Additional prescriptions documented in Palm Care’s dispensing data for I.M. and attributed to a provider at La Maestra on a date after February 27, 2018, which was when I.M. had last been seen at La Maestra, were for Vitamin D3, Lisinopril, Levothyroxine, Fish Oil Conc 1,000 mg, Clopidogrel 75 mg, and Vitamin B-12 1,000 mcg.

88. **Patient I.S.** Of the 12 false prescriptions identified by La Maestra, four were for I.S. As of August of 2018, I.S. had last been seen at La Maestra on April 17, 2018. The Palm Care refill request forms were for Rx # 133150, Rx # 133149, Rx #133157, and Rx #133158:

a) **Mapap.** Rx # 133150 was for Mapap 325 mg recorded as initially dispensed by Respondent Kala. La Maestra had last authorized this medication for I.S. on October 15, 2016, at which time 3 refills were authorized. The request form *obtained from Palm Care* during the Board investigation of the false prescription indicated as follows:

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
4/19/18	4/19/18	90	0	
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
3/23/18	3/23/18	90	0	1

///

///

<sup>14</sup> No request forms for this medication were secured during the Board’s investigation.



1 The prescription history information in the form *obtained from La Maestra*, which accordingly  
 2 lacked an indication the request was approved, was otherwise consistent with the above content.  
 3 The prescription history information contained in Palm Care's *dispensing data* for this medication  
 4 indicated as follows<sup>15</sup>:

Rx Num.	Date Written	Date Filled	Quantity	Refill Num.	Days Supply
140155	4/19/2018	4/19/2018	90	0	30
133150	3/23/2018	3/23/2018	90	0	30
84351*	8/22/2017	2/25/2018	90	7	30
84351*	8/22/2017	1/29/2018	90	6	30
84351*	8/22/2017	1/3/2018	90	5	30
84351*	8/22/2017	12/6/2017	90	4	30
84351*	8/22/2017	11/9/2017	90	3	30
84351*	8/22/2017	10/15/2017	90	2	30
84351*	8/22/2017	9/18/2017	90	1	30
84351*	8/22/2017	8/22/2017	90	0	30
48651*	2/20/2017	7/26/2017	90	6	30
48651*	2/20/2017	6/29/2017	90	5	30
48651*	2/20/2017	6/2/2017	90	4	30
48651*	2/20/2017	5/8/2017	90	3	30
48651*	2/20/2017	4/17/2017	90	2	30
48651*	2/20/2017	3/20/2017	90	1	30
48651*	2/20/2017	2/20/2017	90	0	30

22 b) **Vitamin B-12.** Rx # 133149 was for Vitamin B-12 1,000 MCG recorded as  
 23 initially dispensed by Respondent Kala. La Maestra had last authorized this medication for I.S.  
 24 on August 13, 2016, at which time 5 refills were authorized. The request form *obtained from*  
 25 *Palm Care* during the Board investigation of the false prescription indicated as follows:

26 ///

27 <sup>15</sup> For this table, Rx Numbers which appear with an asterisk indicate a prescription authorization  
 28 that is both not attributed to a provider at La Maestra, and is attributed to Dr. L. Rouel by Palm  
 Care's dispensing data.

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
4/19/18	4/19/18	60	0	
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
3/23/18	3/23/18	60	0	1

The prescription history information in the form *obtained from La Maestra*, which accordingly lacked an indication the request was approved, was otherwise consistent with the above content.

The prescription history information contained in Palm Care’s *dispensing data* for this medication indicated as follows<sup>16</sup>:

Rx Num.	Date Written	Date Filled	Quantity	Refill Num.	Days Supply
140154	4/19/2018	4/19/2018	60	0	30
133149	3/23/2018	3/23/2018	60	0	30
84348*	8/22/2017	2/25/2018	60	7	30
84348*	8/22/2017	1/29/2018	60	6	30
84348*	8/22/2017	1/3/2018	60	5	30
84348*	8/22/2017	12/6/2017	60	4	30
84348*	8/22/2017	11/9/2017	60	3	30
84348*	8/22/2017	10/15/2017	60	2	30
84348*	8/22/2017	9/18/2017	60	1	30
84348*	8/22/2017	8/22/2017	60	0	30
48649*	2/20/2017	7/26/2017	60	6	30
48649*	2/20/2017	6/29/2017	60	5	30
48649*	2/20/2017	6/2/2017	60	4	30
48649*	2/20/2017	5/8/2017	60	3	30
48649*	2/20/2017	4/17/2017	60	2	30
48649*	2/20/2017	3/20/2017	60	1	30
48649*	2/20/2017	2/20/2017	60	0	30

<sup>16</sup> For this table, Rx Numbers which appear with an asterisk indicate a prescription authorization that is both not attributed to a provider at La Maestra, and is attributed to Dr. L. Rouel.

1                   c) **Meclizine.** Rx # 133157 was for Meclizine 25 mg recorded as initially  
 2 dispensed by Respondent Kala. La Maestra had never authorized this medication for I.S. The  
 3 request form *obtained from Palm Care* during the Board investigation of the false prescription  
 4 indicated as follows:

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
4/19/18	4/19/18	40	0	
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
3/23/18	3/23/18	40	0	1

11 The prescription history information in the form *obtained from La Maestra*, which accordingly  
 12 lacked an indication the request was approved, was otherwise consistent with the above content.  
 13 The prescription history information contained in Palm Care’s *dispensing data* for this medication  
 14 indicated as follows:

Rx Num.	Date Written	Date Filled	Quantity	Refill Num.	Days Supply
140151	4/19/2018	4/19/2018	40	0	30
133157	3/23/2018	3/23/2018	40	0	30
117881*	1/19/2018	2/25/2018	40	1	30
117881*	1/19/2018	1/19/2018	40	0	30

20                   d) **Cyclobenzaprine.** Rx # 133158 was for Cyclobenzaprine 10 mg recorded as  
 21 initially dispensed by Respondent Kala. La Maestra had last authorized this medication for I.S.  
 22 on August 13, 2016, at which time 3 refills were authorized. The request form *obtained from*  
 23 *Palm Care* during the Board investigation of the false prescription indicated as follows:

24 ///  
 25 ///  
 26 ///  
 27 ///  
 28 ///

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
4/19/18	4/19/18	60	0	
History				
Date Written	Last Filled	Quantity	Refill Auth	Tines Disp.
3/23/18	3/23/18	60	0	1

The prescription history information in the form *obtained from La Maestra*, which accordingly lacked an indication the request was approved, was otherwise consistent with the above content. The prescription history information contained in Palm Care’s *dispensing data* for this medication indicated as follows<sup>17</sup>:

Rx Num.	Date Written	Date Filled	Quantity	Refill Num.	Days Supply
140158	4/19/2018	4/19/2018	60	0	30
133158	3/23/2018	3/23/2018	60	0	30
108439*	12/6/2017	1/29/2018	60	2	30
108439*	12/6/2017	1/3/2018	60	1	30
108439*	12/6/2017	12/6/2017	60	0	30
102800*	11/9/2017	11/9/2017	60	0	30
62301*	5/8/2017	10/15/2017	60	6	30
62301*	5/8/2017	9/18/2017	60	5	30
62301*	5/8/2017	8/22/2017	60	4	30
62301*	5/8/2017	7/26/2017	60	3	30
62301*	5/8/2017	6/29/2017	60	2	30
62301*	5/8/2017	6/2/2017	60	1	30
62301*	5/8/2017	5/8/2017	60	0	30
34446*	11/3/2016	4/17/2017	60	6	30
34446*	11/3/2016	3/20/2017	60	5	30
34446*	11/3/2016	2/20/2017	60	4	30

<sup>17</sup> For this table, Rx Numbers which appear with an asterisk indicate a prescription authorization that is both not attributed to a provider at La Maestra, and is attributed to Dr. L. Rouel.

89. **Patient K.B.** From the 12 false prescriptions identified by La Maestra, four were for K.B. As of August of 2018, K.B. had last been seen at La Maestra on October 4, 2017. The Palm Care refill request forms were for Rx # 129545, Rx # 126232, Rx # 126233, and Rx # 136394:

a) **Nystop.** Rx # 129545 was for Nystop 100,000 units/gram recorded as initially dispensed by Respondent Kala. La Maestra had never authorized this medication for K.B. The request form *obtained from Palm Care* during the Board investigation of the false prescription indicated as follows:

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
6/15/18	[illegible]	30	0	
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
3/9/18	5/21/18	90	2	3

The prescription history information in the form *obtained from La Maestra*, which accordingly lacked an indication the request was approved, was for Rx # 154976 and indicated as follows:

Authorization/Request				
Date of Rqst	Date Approved	Quantity	Refill Auth.	
7/30/18		30		
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
6/15/18	7/11/18	60	1	2

The prescription history information contained in Palm Care's *dispensing data* for this medication indicated as follows:

///  
///  
///  
///

Rx Num.	Date Written	Date Filled	Quantity	Refill Num.	Days Supply
154976*	6/15/2018	7/11/2018	30	1	30
154976*	6/15/2018	6/15/2018	30	0	30
129545*	3/9/2018	5/21/2018	30	2	30
129545*	3/9/2018	4/22/2018	30	1	30
129545*	3/9/2018	3/26/2018	30	0	30

b) **Mirtazapine.** Rx # 126232 was for Mirtazapine 15 mg recorded as initially dispensed by Respondent Kala. La Maestra had never authorized this medication for K.B. The request form *obtained from Palm Care* during the Board investigation of the false prescription indicated as follows:

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
6/15/18	6/15/18	30	0	
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
2/26/18	5/21/18	120	3	4

The prescription history information in the form *obtained from La Maestra*, which accordingly lacked an indication the request was approved, was for Rx # 154979 and indicated as follows:

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
8/7/18		30		
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
6/15/18	7/11/18	60	1	2

The prescription history information contained in Palm Care's *dispensing data* for this medication indicated as follows:

///

Rx Num.	Date Written	Date Filled	Quantity	Refill Num.	Days Supply
209763*	2/13/2019	1/28/2020	30	3	30
209763*	2/13/2019	1/2/2020	30	2	30
209763*	2/13/2019	12/5/2019	30	1	30
209763*	2/13/2019	11/8/2019	30	0	30
192628*	11/27/2018	10/13/2019	30	4	30
267384*		10/11/2019	[Cancelled]		
220896*	4/2/2019	9/17/2019	30	6	30
220896*	4/2/2019	8/21/2019	30	5	30
220896*	4/2/2019	7/25/2019	30	4	30
220896*	4/2/2019	6/28/2019	30	3	30
220896*	4/2/2019	6/2/2019	30	2	30
220896*	4/2/2019	4/30/2019	30	1	30
220896*	4/2/2019	4/2/2019	30	0	30
192628*	11/27/2018	3/8/2019	30	3	30
192628*	11/27/2018	2/8/2019	30	2	30
192628*	11/27/2018	12/24/2018	30	1	30
192628*	11/27/2018	11/27/2018	30	0	30
154979*	6/15/2018	10/17/2018	30	4	30
154979*	6/15/2018	9/20/2018	30	3	30
154979*	6/15/2018	8/27/2018	30	2	30
154979*	6/15/2018	7/11/2018	30	1	30
154979*	6/15/2018	6/15/2018	30	0	30
126232*	2/26/2018	5/21/2018	30	3	30
126232*	2/26/2018	4/22/2018	30	2	30
126232*	2/26/2018	3/26/2018	30	1	30
126232*	2/26/2018	2/26/2018	30	0	30

In addition, Dr. Cabreros confirmed that Rx # 154979, the authorization for which was attributed to Dr. Atallah at Family Health Centers of San Diego, was false.

///

c) **Prazosin.** Rx # 126233 was for Prazosin 1 mg recorded as initially dispensed by Respondent Kala. La Maestra had last authorized this medication for K.B on December 20, 2016, at which time 3 refills were authorized. The request form *obtained from Palm Care* during the Board investigation of the false prescription indicated as follows:

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
6/15/18	6/15/18	30	0	
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
2/26/18	5/21/18	120	3	4

The prescription history information in the form *obtained from La Maestra*, which accordingly lacked an indication the request was approved, was for Rx # 154975 and indicated as follows:

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
7/30/18		30		
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
6/15/18	7/11/18	60	1	2

The prescription history information contained in Palm Care's *dispensing data* for this medication indicated as follows:

Rx Num.	Date Written	Date Filled	Quantity	Refill Num.	Days Supply
209762*	2/13/2019	1/28/2020	30	2	30
209762*	2/13/2019	1/2/2020	30	1	30
209762*	2/13/2019	12/5/2019	30	0	30
192627*	11/27/2018	11/8/2019	30	4	30
267383*		10/11/2019	[Cancelled]		
220897*	4/2/2019	9/17/2019	30	6	30
220897*	4/2/2019	8/21/2019	30	5	30



1	220897*	4/2/2019	7/25/2019	30	4	30
2	220897*	4/2/2019	6/28/2019	30	3	30
3	220897*	4/2/2019	6/2/2019	30	2	30
4	220897*	4/2/2019	5/6/2019	30	1	30
5	220897*	4/2/2019	4/7/2019	30	0	30
6	192627*	11/27/2018	3/15/2019	30	3	30
7	192627*	11/27/2018	2/16/2019	30	2	30
8	192627*	11/27/2018	1/18/2019	30	1	30
9	192627*	11/27/2018	12/14/2018	30	0	30
10	154975*	6/15/2018	7/11/2018	30	1	30
11	154975*	6/15/2018	6/15/2018	30	0	30
12	126233*	2/26/2018	5/21/2018	30	3	30
13	126233*	2/26/2018	4/23/2018	30	2	30
14	126233*	2/26/2018	3/26/2018	30	1	30
15	126233*	2/26/2018	2/26/2018	30	0	30

15 In addition, Dr. Cabreros confirmed that Rx # 154975, the authorization for which was attributed  
16 to Dr. Atallah at Family Health Centers of San Diego, was false.

17           d) **Fluticasone.** Rx # 136394 was for Fluticasone 50 mcg recorded as initially  
18 dispensed by Respondent Kala. La Maestra had last authorized this medication for K.B. on  
19 September 26, 2017, at which time 1 refill was authorized. The request form *obtained from Palm*  
20 *Care* during the Board investigation of the false prescription indicated as follows:

21 Authorization/Request					
22 Date of Request		Date Approved	Quantity	Refill Auth.	
23 6/15/18		6/15/18	16	0	
24 History					
25 Date Written		Last Filled	Quantity	Refill Auth.	Times Disp.
26 4/4/18		5/19/18	32	1	2

27 The prescription history information in the form *obtained from La Maestra*, which accordingly  
28 lacked an indication the request was approved, was for Rx # 154978 and indicated as follows:

Authorization/Request				
Date of Request	Date Approved	Quantity	Refill Auth.	
7/30/18		16		
History				
Date Written	Last Filled	Quantity	Refill Auth.	Times Disp.
6/15/18	7/11/18	32	1	2

The prescription history information contained in Palm Care’s *dispensing data* for this medication indicated as follows:

Rx Num.	Date Written	Date Filled	Quantity	Refill Num.	Days Supply
275071*	11/11/2019	1/28/2020	16	3	30
275071*	11/11/2019	1/2/2020	16	2	30
275071*	11/11/2019	12/5/2019	16	1	30
275071*	11/11/2019	11/11/2019	16	0	30
154978	6/15/2018	7/11/2018	16	1	30
154978	6/15/2018	6/15/2018	16	0	30
136394	4/4/2018	5/19/2018	16	1	30
136394	4/4/2018	4/22/2018	16	0	30
92644	9/26/2017	3/26/2018	16	1	30
92644	9/26/2017	9/26/2017	16	0	30

90. Palm Care’s prescription delivery practices were also reviewed as part of the La Maestra investigation. The pharmacy had delivery vehicles on routes which regularly ended after the pharmacy closed with prescriptions still in the delivery vehicle at the end of the route. Those drugs were then left in the vehicle overnight outside the pharmacy until the pharmacist on duty the following morning brought them in. The delivery vehicles used by Palm Care to store undelivered prescriptions were not temperature controlled overnight and the environmental conditions were not monitored.

///  
///  
///

1 **LA MESA CARDIAC CENTER INVESTIGATION**

2 91. On or about November 20, 2018, the Board received a complaint from La Mesa  
3 Cardiac Center concerning prescriptions filled at Palm Care.

4 92. Palm Care's records reflect that Furosemide was given to patient N.Y. under Rx #  
5 185096 on October 23, 2018, with instructions to take one tablet "every day blood thinner."  
6 Furosemide is not a blood thinner and was therefore incorrectly labeled. This incorrect label  
7 appears to have been copied from Rx # 185097 for Aspirin EC, also given to patient N.Y.

8 93. Palm Care's records reflect that Lisinopril was given to patient N.Y. under Rx #  
9 185095 with instructions to take 2 tablets daily. The prescription was filled on October 23, 2018,  
10 and the fourth refill of 60 tablets was given on February 5, 2019. In total 300 tablets were given  
11 in this 105-day period. Palm Care provided a hard copy of the handwritten prescription which  
12 authorized a total of 120 tablets.

13 94. Palm Care's records reflect that Carvedilol was given to patient D.A. with  
14 instructions to take 2 tablets daily. Rx # 132916 was filled on April 18, 2018, and the sixth refill  
15 of 60 tablets was given on September 25, 2018. In total, 420 tablets were given in this 160-day  
16 period. Thus, Palm Care dispensed drugs far in excess of the amounts authorized by the  
17 prescriber.

18 95. Palm Care's records reflect that Cerovite Senior Multivitamin was dispensed to  
19 patient M.I., with instructions to take 1 tablet daily. Rx # 160109 was filled on July 9, 2018, and  
20 the second refill of 100 tablets was given on August 31, 2018. In total, 300 tablets were given in  
21 this 53-day period. Thus, Palm Care dispensed drugs far in excess of the amounts authorized by  
22 the prescriber.

23 96. Palm Care's dispensing data reflects that a new Cerovite Senior Multivitamin  
24 prescription was authorized on September 4, 2018, and was first issued to M.I. on September 26,  
25 2018 under Rx # 173562, with the second 100 tablet refill given on November 18, 2018. In total,  
26 300 tablets were given in this second 53-day period. Thus, Palm Care dispensed drugs far in  
27 excess of the amounts authorized by the prescriber. The written prescription for Rx # 173562,  
28 dispensed by Respondent Cortez-Gomez, was not dated except under a January 1, 2013 header.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**PATIENT M.A. INVESTIGATION**

97. On or about January 24, 2020, the Board received a complaint concerning Palm Care from a patient identified here by the initials M.A. M.A. reported that Palm Care had dispensed Metoprolol to him on or about December 8, 2019 instead of metformin, and he was hospitalized as a result of Palm Care’s error of dispensing the wrong medication. Metoprolol is indicated for use in the treatment of high blood pressure (hypertension). Metformin is indicated for use in the treatment of diabetes.

98. In the course of the Board’s investigation, Respondent Alkazaki was asked to provide documents related to patient M.A. Respondent Alkazaki provided an electronic prescription record for M.A. dated September 18, 2019 for Metformin with 12 additional refills authorized.

99. The dispensing record provided by Respondent Alkazaki shows Metformin 1,000 mg was dispensed on September 18, 2019 and refilled on October 15, 2019, under Rx # 261262. The dispensing record shows that under Rx # 261262 M.A. was then dispensed Metoprolol Tartrate 100 mg on November 11, 2019 and again on December 8, 2019 with instructions to take “for the diabetes.” Metoprolol is indicated for use in the treatment of hypertension and was therefore incorrectly labeled. The dispensing record shows that the two occasions under Rx # 261262 were the only record of Metoprolol being dispensed to M.A.

**PATIENT F.S. INVESTIGATION**

100. On or about October 27, 2020 the Board received a complaint concerning Palm Care from a patient identified here by the initials F.S. F.S. reported that Palm Care had been dispensed the blood thinner Eliquis incorrectly labeled with the instructions “for diabetes.” F.S. reported that as a result of Palm Care’s error, he took Eliquis every time his blood sugar was high, which caused excess bleeding and bruising, including exacerbating bleeding from a stomach ulcer. F.S. reported he only discovered Palm Care’s error when he transferred to another pharmacy and the pharmacist there consulted him properly with accurate instructions on the Eliquis label.

101. In the course of the Board’s investigation of a different complaint against Palm Care in February of 2020, Respondent Alkazaki provided Palm Care’s dispensing data. The version of Palm Care’s dispensing data provided at that time reflected that Respondent Alkazaki dispensed

1 Eliquis under Rx # 266299 to F.S. on October 8, 2019 with directions to “Take one tablet by  
2 mouth twice a day for diabetes.” Based on this dispensing data, October 8, 2019 was the first  
3 date Eliquis had been dispensed to F.S. under Rx # 266299. This dispensing data provided by  
4 Palm Care further reflected that this transaction for Eliquis had been reversed from the insurance  
5 billing after it was filled. Palm Care’s dispensing data also reflected that F.S. had separately been  
6 dispensed Eliquis under Rx # 258384 with directions to “Take one tablet by mouth twice daily  
7 blood thinner” on September 5, 2019, October 4, 2019, October 29, 2019, November 25, 2019,  
8 December 21, 2019, and January 17, 2020.

9 102. On or about December 16, 2020, in response to the Board’s request for documents in  
10 connection with the F.S. Investigation, Respondent Alkazaki provided Palm Care’s dispensing  
11 data for 2020, Palm Care’s patient profile for F.S., and a copy of a backtag and prescription label  
12 bearing Rx # 266299. The backtag sticker showed a print date of December 10, 2020. The  
13 prescription label was dated June 25, 2020. The directions on each of these documents was to  
14 “Take one tablet by mouth twice a day blood thinner.” Palm Care’s 2020 dispensing data, and the  
15 patient profile for F.S. from 2018 through 2020, reflected that Eliquis had first been dispensed to  
16 F.S. under Rx # 266299 on February 13, 2020 with directions to “Take one tablet by mouth twice  
17 a day blood thinner.” The October 8, 2019 Eliquis transaction under Rx # 266299 containing  
18 instructions to take “for diabetes” which exists in the dispensing data Palm Care provided in  
19 February 2020 was entirely omitted from the material Respondent Alkazaki provided in  
20 December 2020 in connection with the F.S. Investigation.

21 103. Respondent Alkazaki included a written statement concerning patient F.S. with the  
22 prescription records provided to the Board in December 2020. Respondent Alkazaki’s written  
23 statement indicated F.S. had complained to Palm Care in April 2020 about his prescription under  
24 Rx # 266299 for Eliquis. Respondent Alkazaki’s statement asserted that at the time F.S. had,  
25 “mistakenly believed that the Eliquis 5 mg prescription he got from the Palm Care Pharmacy a  
26 few days prior was for diabetes and insisted that we gave him the wrong prescription.” There was  
27 no mention of the October 8, 2019 transaction for Eliquis, which once existed under Rx # 266299,  
28 directing its use “for diabetes” in Respondent Alkazaki’s written statement.

**PATIENT A.A. INVESTIGATION**

104. On or about November 30, 2022, the Board received a complaint concerning Palm Care from a patient identified here by the initials A.A. A.A.'s daughter reported that Palm Care had delivered two blood pressure medications to him when he should have received neither drug because his doctor had switched him to a different medication, and because A.A. had switched to another pharmacy. A.A. took the two medications that Palm Care had delivered to him, Rx # 535337 for Losartan and Rx # 535336 for Amlodipine, as well as the third medication, Lisinopril, that had been properly dispensed by another pharmacy. A.A. experienced temporary lightheadedness as a result of the drop in blood pressure occasioned by the drugs.

105. On April 27, 2023, a Board inspection of Palm Care was performed to gather information on the patient A.A. dispensing error. Palm Care's records confirmed that Rx # 535337 and Rx # 535336 were dispensed to A.A. on November 29, 2022. Prior to Rx # 535337 and Rx # 535336, Palm Care had last dispensed a prescription to A.A. on July 22, 2022.

106. The supporting electronic prescription in Palm Care's records for Rx # 535337 and Rx # 535336 was for an entirely different patient, patient G.M., who shared the same date of birth as A.A.<sup>18</sup>

107. Respondent Alkazaki arrived at the pharmacy during the inspection on April 27, 2023, and would intermittently enter into his office and remain inside behind a closed door. During the inspection, A.A.'s daughter emailed one of the Board investigators to inform him that Respondent Alkazaki had just called A.A.'s household. She explained that in the call, Respondent Alkazaki sounded very upset while questioning them about making a report to the Board, and that he also said words to the effect of, "We are Arabs, supposed to be family."

///

///

///

///

---

<sup>18</sup> Palm Care's *dispensing data* through April 27, 2023 contained no record of any prescription ever being dispensed to G.M.

1           **CASH COMPROMISE OF CONTROLLED SUBSTANCE ACT VIOLATIONS**

2           108. On or about April 30, 2024, Palm Care entered into an agreement with the United  
3 States Department of Justice for the \$350,000 cash compromise of allegations that Palm Care had  
4 violated the Controlled Substances Act. The United States Department of Justice, acting on  
5 behalf of the DEA, alleged that Palm Care engaged in violations of 21 U.S.C. §§801-904 of the  
6 Controlled Substances Act through deficient record-keeping practices, failing to properly account  
7 for significant quantities of controlled substances, and by selling certain products without the  
8 necessary training and certification.

9           109. Contemporaneous with the cash compromise agreement with the United States  
10 Department of Justice, Palm Care entered into a Memorandum of Agreement with the DEA  
11 concerning the same Controlled Substances Act violations, to be in effect for a two year period,  
12 and which imposed various requirements on Palm Care, including quarterly reconciliation of  
13 schedule II controlled substances on hand.

14           110. The Controlled Substances Act violations alleged against Palm Care were initially  
15 uncovered by a 2020 DEA audit, and after Palm Care was given an opportunity to bring itself into  
16 compliance, the violations were found to persist at the time of a 2022 DEA audit. The DEA’s  
17 audits of Palm Care identified inventory shortages of tens or hundreds of tablets or capsules with  
18 respect to some controlled substances, and with respect to others, hundreds or thousands of excess  
19 tablets. The controlled substances the subject of the DEA’s audit included hydrocodone,  
20 carisoprodol, tramadol, pregabalin, oxycodone, and alprazolam.

21       ///

22       ///

23       ///

24       ///

25       ///

26       ///

27       ///

28       ///



1 **FIRST CAUSE FOR DISCIPLINE**

2 **(Acts Involving Dishonesty, Fraud or Deceit – Molina Investigation – Respondent Palm**  
3 **Care & Respondent Alkazaki)**

4 111. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
5 section 4301, subdivision (f), for falsifying prior authorization requests, for falsifying, dispensing  
6 and billing unauthorized Metformin ER Gastric prescriptions, and for submitting prescription  
7 billings under nurse practitioner S.C.’s federally issued identifiers without authorization,  
8 described in the paragraphs above and incorporated herein as though set forth in full.

9 **SECOND CAUSE FOR DISCIPLINE**

10 **(Making or Signing Document that Falsely Represents – Molina Investigation – Respondent**  
11 **Palm Care & Respondent Alkazaki)**

12 112. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
13 section 4301, subdivision (g), for falsifying prior authorization requests, for falsifying, dispensing  
14 and billing unauthorized Metformin ER Gastric prescriptions, and for submitting prescription  
15 billings under nurse practitioner S.C.’s federally issued identifiers without authorization,  
16 described in the paragraphs above and incorporated herein as though set forth in full.

17 **THIRD CAUSE FOR DISCIPLINE**

18 **(Insurance Fraud – Molina Investigation – Respondent Palm Care & Respondent Alkazaki)**

19 113. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
20 section 4301, subdivisions (j) and/or (o), for violating Code section 810 by knowingly preparing,  
21 making or subscribing a writing with the intent to have it used in support of a false or fraudulent  
22 claim or knowingly making or causing to be made a false or fraudulent claim, or submitting a  
23 fraudulent claim for a health care benefit in violation of section 550 (a) of the Penal Code with  
24 respect to the falsified prior authorization requests, falsified Metformin ER Gastric prescriptions,  
25 and the prescriptions billed under nurse practitioner S.C.’s federally issued identifiers without  
26 authorization, described in the paragraphs above and incorporated herein as though set forth in  
27 full.

28 ///



1 **FOURTH CAUSE FOR DISCIPLINE**

2 **(Unauthorized Prescriptions – Molina Investigation – Respondent Palm Care & Respondent**  
3 **Alkazaki)**

4 114. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
5 section 4301, subdivisions (j) and/or (o), for violating, for Code sections 4059 and 4063, and  
6 section 1716 of Title 16 of the California Code of Regulations by dispensing and billing  
7 unauthorized Metformin ER Gastric prescriptions, described in the paragraphs above and  
8 incorporated herein as though set forth in full.

9 **FIFTH CAUSE FOR DISCIPLINE**

10 **(Forgery – Molina Investigation – Respondent Palm Care & Respondent Alkazaki)**

11 115. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
12 section 4301, subdivisions (j) and/or (o), for violating Code section 4324, subdivision (a), for  
13 forging prior authorization requests and Metformin ER Gastric prescriptions, described in the  
14 paragraphs above and incorporated herein as though set forth in full.

15 **SIXTH CAUSE FOR DISCIPLINE**

16 **(Unprofessional Conduct – Molina Investigation – Respondent Palm Care & Respondent**  
17 **Alkazaki)**

18 116. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
19 section 4301 for unprofessional conduct for falsifying prior authorization requests, for falsifying,  
20 dispensing and billing unauthorized Metformin ER Gastric prescriptions, and for submitting  
21 prescription billings under nurse practitioner S.C.’s federally issued identifiers without  
22 authorization, described in the paragraphs above and incorporated herein as though set forth in  
23 full.

24 ///

25 ///

26 ///

27 ///

28 ///

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**SEVENTH CAUSE FOR DISCIPLINE**

**(Acts Involving Dishonesty, Fraud or Deceit – Qlarant Investigation – Respondent Palm Care National City & Respondent Alkazaki)**

117. Respondents Palm Care National City and Alkazaki are subject to disciplinary action under Code section 4301, subdivision (f), for creating and furnishing falsified Metformin ER Gastric inventory and acquisition records, and for fraudulent dispensing and billing activities wherein sales of Metformin ER Gastric exceeded actual acquisitions, described in the paragraphs above and incorporated herein as though set forth in full.

**EIGHTH CAUSE FOR DISCIPLINE**

**(Making or Signing Document that Falsely Represents – Qlarant Investigation – Respondent Palm Care National City & Respondent Alkazaki)**

118. Respondents Palm Care National City and Alkazaki are subject to disciplinary action under Code section 4301, subdivision (g), for creating and furnishing falsified Metformin ER Gastric inventory and acquisition records, and for fraudulent dispensing and billing activities wherein sales of Metformin ER Gastric exceeded acquisitions, described in the paragraphs above and incorporated herein as though set forth in full.

**NINTH CAUSE FOR DISCIPLINE**

**(Insurance Fraud – Qlarant Investigation – Respondent Palm Care National City & Respondent Alkazaki)**

119. Respondents Palm Care National City and Alkazaki are subject to disciplinary action under Code section 4301, subdivisions (j) and/or (o), for violating Code section 810 by knowingly preparing, making or subscribing a writing with the intent to have it used in support of a false or fraudulent claim or knowingly making or causing to be made a false or fraudulent claim, or submitting a fraudulent claim for a health care benefit in violation of section 550 (a) of the Penal Code with respect to fraudulent dispensing and billing activities wherein sales of Metformin ER Gastric exceeded actual acquisitions, described in the paragraphs above and incorporated herein as though set forth in full.

///

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**TENTH CAUSE FOR DISCIPLINE**

**(Subvert or Attempt to Subvert an Investigation – Qlarant Investigation – Respondent Palm Care National City & Respondent Alkazaki)**

120. Respondents Palm Care National City and Alkazaki are subject to disciplinary action under Code section 4301, subdivision (q), for subverting or attempting to subvert an investigation of the Board by creating and furnishing falsified Metformin ER Gastric inventory and acquisition records, described in the paragraphs above and incorporated herein as though set forth in full.

**ELEVENTH CAUSE FOR DISCIPLINE**

**(Incorrect Labeling – Qlarant Investigation – Respondent Palm Care National City & Respondent Alkazaki)**

121. Respondents Palm Care National City and Alkazaki are subject to disciplinary action under Code section 4301, subdivision (j) and/or (o), for violating Code sections 4077(a) and 4076(a)(11), for furnishing dangerous drugs labeled with the incorrect color, shape, or identification code for the tablet dispensed, described in the paragraphs above and incorporated herein as though set forth in full.

**TWELFTH CAUSE FOR DISCIPLINE**

**(Unprofessional Conduct – Qlarant Investigation – Respondent Palm Care National City & Respondent Alkazaki)**

122. Respondents Palm Care National City and Alkazaki are subject to disciplinary action under Code section 4301 for unprofessional conduct for creating and furnishing falsified Metformin ER Gastric inventory and acquisition records, for fraudulent dispensing and billing activities wherein sales of Metformin ER Gastric exceeded actual acquisitions, and for furnishing dangerous drugs labeled with the incorrect color, shape, or identification code for the tablet dispensed, described in the paragraphs above and incorporated herein as though set forth in full.

///  
///  
///  
///

1 **THIRTEENTH CAUSE FOR DISCIPLINE**

2 **(Acts Involving Dishonesty, Fraud or Deceit – Latuda Investigation – Respondent Palm**  
3 **Care & Respondent Alkazaki)**

4 123. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
5 section 4301, subdivision (f), for fraudulent dispensing and billing activities wherein sales of  
6 Latuda exceeded actual acquisitions, described in the paragraphs above and incorporated herein  
7 as though set forth in full.

8 **FOURTEENTH CAUSE FOR DISCIPLINE**

9 **(Making or Signing Document that Falsely Represents – Latuda Investigation – Respondent**  
10 **Palm Care & Respondent Alkazaki)**

11 124. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
12 section 4301, subdivision (g), for fraudulent dispensing and billing activities wherein sales of  
13 Latuda exceeded acquisitions, described in the paragraphs above and incorporated herein as  
14 though set forth in full.

15 **FIFTEENTH CAUSE FOR DISCIPLINE**

16 **(Insurance Fraud – Latuda Investigation – Respondent Palm Care & Respondent Alkazaki)**

17 125. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
18 section 4301, subdivisions (j) and/or (o), for violating Code section 810 by knowingly preparing,  
19 making or subscribing a writing with the intent to have it used in support of a false or fraudulent  
20 claim or knowingly making or causing to be made a false or fraudulent claim, or submitting a  
21 fraudulent claim for a health care benefit in violation of section 550 (a) of the Penal Code with  
22 respect to fraudulent dispensing and billing activities wherein sales of Latuda exceeded actual  
23 acquisitions, described in the paragraphs above and incorporated herein as though set forth in full.

24 ///

25 ///

26 ///

27 ///

28 ///



1 **SEVENTEENTH CAUSE FOR DISCIPLINE**

2 **(Acts Involving Dishonesty, Fraud or Deceit – La Maestra Investigation – Respondent Palm**  
3 **Care & Respondent Alkazaki)**

4 127. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
5 section 4301, subdivision (f), for falsifying, dispensing and billing unauthorized prescriptions  
6 with respect to patients M.K., S.S., C.B., I.M., I.S., and K.B, for excessively furnishing drugs to  
7 patients in relation to the use rate authorized, and billing insurers, with respect to patients M.K.,  
8 S.S., C.B., I.M., I.S., K.B., and X, and for creating and producing manipulated pharmacy records  
9 in connection with an investigation of the Board into the 12 request refill authorization forms  
10 identified above and into Rx # 157230, described in the paragraphs above and incorporated herein  
11 as though set forth in full.

12 **EIGHTEENTH CAUSE FOR DISCIPLINE**

13 **(Making or Signing Document that Falsely Represents – La Maestra Investigation –**  
14 **Respondent Palm Care & Respondent Alkazaki)**

15 128. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
16 section 4301, subdivision (g), for falsifying, dispensing and billing unauthorized prescriptions  
17 with respect to patients M.K., S.S., C.B., I.M., I.S., and K.B., and for creating and producing  
18 manipulated pharmacy records in connection with an investigation of the Board into the 12  
19 request refill authorization forms identified above and into Rx # 157230, described in the  
20 paragraphs above and incorporated herein as though set forth in full.

21 **NINETEENTH CAUSE FOR DISCIPLINE**

22 **(Insurance Fraud – La Maestra Investigation – Respondent Palm Care & Respondent**  
23 **Alkazaki)**

24 129. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
25 section 4301, subdivisions (j) and/or (o), for violating Code section 810 by knowingly preparing,  
26 making or subscribing a writing with the intent to have it used in support of a false or fraudulent  
27 claim or knowingly making or causing to be made a false or fraudulent claim, or submitting a  
28 fraudulent claim for a health care benefit in violation of section 550 (a) of the Penal Code with

1 respect to the falsified prescriptions for patients M.K., S.S., C.B., I.M., I.S., and K.B., and the  
2 drugs furnished in excess of the use rate authorized to patients M.K., S.S., C.B., I.M., I.S., K.B,  
3 and X, described in the paragraphs above and incorporated herein as though set forth in full.

4 **TWENTIETH CAUSE FOR DISCIPLINE**

5 **(Unauthorized Prescriptions – La Maestra Investigation – Respondent Palm Care &  
6 Respondent Alkazaki)**

7 130. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
8 section 4301, subdivisions (j) and/or (o), for violating, for Code sections 4059 and 4063, and  
9 section 1716 of Title 16 of the California Code of Regulations by dispensing and billing  
10 unauthorized prescriptions with respect to patients M.K., S.S., C.B., I.M., I.S., and K.B., and  
11 excessively furnishing drugs to patients in relation to the use rate authorized, and billing insurers,  
12 with respect to patients M.K., S.S., C.B., I.M., I.S., K.B, and X, described in the paragraphs  
13 above and incorporated herein as though set forth in full.

14 **TWENTY-FIRST CAUSE FOR DISCIPLINE**

15 **(Forgery – La Maestra Investigation – Respondent Palm Care & Respondent Alkazaki)**

16 131. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
17 section 4301, subdivisions (j) and/or (o), for violating Code section 4324, subdivision (a), for  
18 forging prescriptions with respect to patients M.K., S.S., C.B., I.M., I.S., and K.B., described in  
19 the paragraphs above and incorporated herein as though set forth in full.

20 **TWENTY-SECOND CAUSE FOR DISCIPLINE**

21 **(Subvert or Attempt to Subvert an Investigation – La Maestra Investigation – Respondent  
22 Palm Care & Respondent Alkazaki)**

23 132. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
24 section 4301, subdivision (q), for subverting or attempting to subvert an investigation of the  
25 Board by creating and producing manipulated pharmacy records in connection with an  
26 investigation of the Board into the 12 request refill authorization forms identified above and into  
27 Rx # 157230, described in the paragraphs above and incorporated herein as though set forth in  
28 full.

1 **TWENTY-THIRD CAUSE FOR DISCIPLINE**

2 **(Incorrect Labeling – La Maestra Investigation – Respondent Palm Care & Respondent**  
3 **Alkazaki)**

4 133. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
5 section 4301, subdivisions (j) and/or (o), for violating Code sections 4077(a) and 4076(a)(3), for  
6 furnishing dangerous drugs with the incorrect patient name under Rx # 157230, described in the  
7 paragraphs above and incorporated herein as though set forth in full.

8 **TWENTY-FOURTH CAUSE FOR DISCIPLINE**

9 **(Adulterated Drugs – La Maestra Investigation – Respondent Palm Care & Respondent**  
10 **Alkazaki)**

11 134. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
12 section 4301, subdivisions (j) and/or (o), for violating Health & Safety Code section 111295 and  
13 4169, subdivision (a)(2) for holding and offering for sale drugs that were adulterated within the  
14 meaning of Health and Safety Code section 111255, described in the paragraphs above and  
15 incorporated herein as though set forth in full.

16 **TWENTY-FIFTH CAUSE FOR DISCIPLINE**

17 **(Unprofessional Conduct – La Maestra Investigation – Respondent Palm Care &**  
18 **Respondent Alkazaki)**

19 135. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
20 section 4301 for unprofessional conduct for falsifying, dispensing and billing unauthorized  
21 prescriptions with respect to patients M.K., S.S., C.B., I.M., I.S., and K.B, for excessively  
22 furnishing drugs to patients in relation to the use rate authorized, and billing insurers, with respect  
23 to patients M.K., S.S., C.B., I.M., I.S., K.B., and X, for creating and producing manipulated  
24 pharmacy records in connection with an investigation of the Board into the 12 request refill  
25 authorization forms identified above and into Rx # 157230, for furnishing dangerous drugs with  
26 the incorrect patient name under Rx # 157230, and for holding and offering for sale drugs that  
27 were adulterated, described in the paragraphs above and incorporated herein as though set forth in  
28 full.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**TWENTY-SIXTH CAUSE FOR DISCIPLINE**

**(Acts Involving Dishonesty, Fraud or Deceit – La Mesa Cardiac Investigation – Respondent Palm Care & Respondent Alkazaki)**

136. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code section 4301, subdivision (f), for excessively furnishing drugs to patients in relation to the use rate authorized, and billing insurers, with respect to patients N.Y., D.A., and M.I., described in the paragraphs above and incorporated herein as though set forth in full.

**TWENTY-SEVENTH CAUSE FOR DISCIPLINE**

**(Insurance Fraud – La Mesa Cardiac Investigation – Respondent Palm Care & Respondent Alkazaki)**

137. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code section 4301, subdivisions (j) and/or (o), for violating Code section 810 by knowingly preparing, making or subscribing a writing with the intent to have it used in support of a false or fraudulent claim or knowingly making or causing to be made a false or fraudulent claim, or submitting a fraudulent claim for a health care benefit in violation of section 550 (a) of the Penal Code with respect to the drugs furnished in excess of the use rate authorized to patients N.Y., D.A., M.I., described in the paragraphs above and incorporated herein as though set forth in full.

**TWENTY-EIGHTH CAUSE FOR DISCIPLINE**

**(Unauthorized Prescriptions – La Mesa Cardiac Investigation – Respondent Palm Care & Respondent Alkazaki)**

138. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code section 4301, subdivisions (j) and/or (o), for violating, for Code sections 4059 and 4063, and section 1716 of Title 16 of the California Code of Regulations by excessively furnishing drugs to patients in relation to the use rate authorized, and billing insurers, with respect to patients N.Y., D.A., and M.I., described in the paragraphs above and incorporated herein as though set forth in full.

///  
///

1 **TWENTY-NINTH CAUSE FOR DISCIPLINE**

2 **(Incorrect Labeling – La Mesa Cardiac Investigation – Respondent Palm Care &**  
3 **Respondent Alkazaki)**

4 139. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
5 section 4301, subdivisions (j) and/or (o), for violating Code sections 4077(a) and 4076(a)(2)  
6 and/or (a)(10), for furnishing dangerous drugs with incorrect directions for use and an incorrect  
7 description of the condition or purpose for which the drug was prescribed under Rx # 185096,  
8 described in the paragraphs above and incorporated herein as though set forth in full.

9 **THIRTIETH CAUSE FOR DISCIPLINE**

10 **(Unprofessional Conduct – La Mesa Cardiac Investigation – Respondent Palm Care &**  
11 **Respondent Alkazaki)**

12 140. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
13 section 4301 for unprofessional conduct for excessively furnishing drugs to patients in relation to  
14 the use rate authorized, and billing insurers, with respect to patients N.Y., D.A., and M.I., and for  
15 furnishing dangerous drugs with incorrect directions for use and an incorrect description of the  
16 condition or purpose for which the drug was prescribed under Rx # 185096, described in the  
17 paragraphs above and incorporated herein as though set forth in full.

18 ///

19 ///

20 ///

21 ///

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**THIRTY-THIRD CAUSE FOR DISCIPLINE**

**(Acts Involving Dishonesty, Fraud or Deceit – Patient F.S. Investigation – Respondent Palm Care & Respondent Alkazaki)**

143. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code section 4301, subdivision (f), for creating and producing manipulated pharmacy records in connection with an investigation of the Board into Rx # 266299, described in the paragraphs above and incorporated herein as though set forth in full.

**THIRTY-FOURTH CAUSE FOR DISCIPLINE**

**(Making or Signing Document that Falsely Represents – Patient F.S. Investigation – Respondent Palm Care & Respondent Alkazaki)**

144. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code section 4301, subdivision (g), for creating and producing manipulated pharmacy records in connection with an investigation of the Board into Rx # 266299, described in the paragraphs above and incorporated herein as though set forth in full.

**THIRTY-FIFTH CAUSE FOR DISCIPLINE**

**(Incorrect Labeling – Patient F.S. Investigation – Respondent Palm Care & Respondent Alkazaki)**

145. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code section 4301, subdivisions (j) and/or (o), for violating Code sections 4077(a) and 4076(a)(2) and/or (a)(10), for furnishing dangerous drugs with incorrect directions for use and an incorrect description of the condition or purpose for which the drug was prescribed under Rx # 266299, described in the paragraphs above and incorporated herein as though set forth in full.

**THIRTY-SIXTH CAUSE FOR DISCIPLINE**

**(Subvert or Attempt to Subvert an Investigation – Patient F.S. Investigation – Respondent Palm Care & Respondent Alkazaki)**

146. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code section 4301, subdivision (q), for subverting or attempting to subvert an investigation of the Board by creating and producing manipulated pharmacy records in connection with an

1 investigation of the Board into Rx # 266299, described in the paragraphs above and incorporated  
2 herein as though set forth in full.

3 **THIRTY-SEVENTH CAUSE FOR DISCIPLINE**

4 **(Unprofessional Conduct – Patient F.S. Investigation – Respondent Palm Care &  
5 Respondent Alkazaki)**

6 147. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
7 section 4301 for unprofessional conduct for creating and producing manipulated pharmacy  
8 records in connection with an investigation of the Board into Rx # 266299, and for furnishing  
9 dangerous drugs with incorrect directions for use and an incorrect description of the condition or  
10 purpose for which the drug was prescribed under Rx # 266299, described in the paragraphs above  
11 and incorporated herein as though set forth in full.

12 ///

13 ///

14 ///

15 ///

16 ///

17 ///

18 ///

19 ///

20 ///

21 ///

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///

1 **THIRTY-EIGHTH CAUSE FOR DISCIPLINE**

2 **(Incorrect Labeling – Patient A.A. Investigation – Respondent Palm Care & Respondent**  
3 **Alkazaki)**

4 148. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
5 section 4301, subdivisions (j) and/or (o), for violating Code sections 4077(a) and 4076(a)(3), for  
6 furnishing dangerous drugs with the incorrect patient name under Rx # 535337 and Rx # 535336,  
7 described in the paragraphs above and incorporated herein as though set forth in full.

8 **THIRTY-NINTH CAUSE FOR DISCIPLINE**

9 **(Subvert or Attempt to Subvert an Investigation – Patient A.A. Investigation – Respondent**  
10 **Palm Care & Respondent Alkazaki)**

11 149. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
12 section 4301, subdivision (q), for subverting or attempting to subvert an investigation of the  
13 Board by attempting to dissuade members of A.A.’s household from causing their complaint  
14 related to Rx # 535337 and Rx # 535336 to be investigated, described in the paragraphs above  
15 and incorporated herein as though set forth in full.

16 **FORTIETH CAUSE FOR DISCIPLINE**

17 **(Unprofessional Conduct – Patient A.A. Investigation – Respondent Palm Care &**  
18 **Respondent Alkazaki)**

19 150. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
20 section 4301 for unprofessional conduct for furnishing dangerous drugs with the incorrect patient  
21 name under Rx # 535337 and Rx # 535336, and for attempting to dissuade members of A.A.’s  
22 household from causing their complaint related to Rx # 535337 and Rx # 535336 to be  
23 investigated, described in the paragraphs above and incorporated herein as though set forth in full.

24 **FORTY-FIRST CAUSE FOR DISCIPLINE**

25 **(Cash Compromise of CSA Violations – Respondent Palm Care & Respondent Alkazaki)**

26 151. Respondents Palm Care and Alkazaki are subject to disciplinary action under Code  
27 section 4301, subdivision (m), for the cash compromise of Controlled Substance Act violations,  
28 described in the paragraphs above and incorporated herein as though set forth in full.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**FORTY-SECOND CAUSE FOR DISCIPLINE**

**(Acts Involving Dishonesty, Fraud or Deceit – La Maestra Investigation – Respondent Kala)**

152. Respondent Kala is subject to disciplinary action under Code section 4301, subdivision (f), for falsifying, dispensing and billing unauthorized prescriptions with respect to patients M.K., S.S., C.B., I.M., I.S., and K.B., and for excessively furnishing drugs to patients in relation to the use rate authorized, and billing insurers, with respect to patients M.K., S.S., C.B., I.M., I.S., K.B., and X, described in the paragraphs above and incorporated herein as though set forth in full.

**FORTY-THIRD CAUSE FOR DISCIPLINE**

**(Making or Signing Document that Falsely Represents – La Maestra Investigation – Respondent Kala)**

153. Respondent Kala is subject to disciplinary action under Code section 4301, subdivision (g), for falsifying, dispensing and billing unauthorized prescriptions with respect to patients M.K., S.S., C.B., I.M., I.S., and K.B., described in the paragraphs above and incorporated herein as though set forth in full.

**FORTY-FOURTH CAUSE FOR DISCIPLINE**

**(Insurance Fraud – La Maestra Investigation – Respondent Kala)**

154. Respondent Kala is subject to disciplinary action under Code section 4301, subdivisions (j) and/or (o), for violating Code section 810 by knowingly preparing, making or subscribing a writing with the intent to have it used in support of a false or fraudulent claim or knowingly making or causing to be made a false or fraudulent claim, or submitting a fraudulent claim for a health care benefit in violation of section 550 (a) of the Penal Code with respect to the falsified prescriptions for patients M.K., S.S., C.B., I.M., I.S., and K.B., and the drugs furnished in excess of the use rate authorized to patients M.K., S.S., C.B., I.M., I.S., K.B., and X, described in the paragraphs above and incorporated herein as though set forth in full.

///  
///  
///

1 **FORTY-FIFTH CAUSE FOR DISCIPLINE**

2 **(Unauthorized Prescriptions – La Maestra Investigation – Respondent Kala)**

3 155. Respondent Kala is subject to disciplinary action under Code section 4301,  
4 subdivisions (j) and/or (o), for violating, for Code sections 4059 and 4063, and section 1716 of  
5 Title 16 of the California Code of Regulations by dispensing and billing unauthorized  
6 prescriptions with respect to patients M.K., S.S., C.B., I.M., I.S., and K.B., and excessively  
7 furnishing drugs to patients in relation to the use rate authorized, billed to insurers, with respect to  
8 patients M.K., S.S., C.B., I.M., I.S., K.B, and X, described in the paragraphs above and  
9 incorporated herein as though set forth in full.

10 **FORTY-SIXTH CAUSE FOR DISCIPLINE**

11 **(Forgery – La Maestra Investigation – Respondent Kala)**

12 156. Respondent Kala is subject to disciplinary action under Code section 4301,  
13 subdivisions (j) and/or (o), for violating Code section 4324, subdivision (a), for forging  
14 prescriptions with respect to patients M.K., S.S., C.B., I.M., I.S., and K.B., described in the  
15 paragraphs above and incorporated herein as though set forth in full.

16 **FORTY-SEVENTH CAUSE FOR DISCIPLINE**

17 **(Unprofessional Conduct – La Maestra Investigation – Respondent Kala)**

18 157. Respondent Kala is subject to disciplinary action under Code section 4301 for  
19 unprofessional conduct for falsifying, dispensing and billing unauthorized prescriptions with  
20 respect to patients M.K., S.S., C.B., I.M., I.S., and K.B, and for excessively furnishing drugs to  
21 patients in relation to the use rate authorized, billed to insurers, with respect to patients M.K.,  
22 S.S., C.B., I.M., I.S., K.B., and X, described in the paragraphs above and incorporated herein as  
23 though set forth in full.

24 ///  
25 ///  
26 ///  
27 ///  
28 ///



1 **FORTY-EIGHTH CAUSE FOR DISCIPLINE**

2 **(Unauthorized Prescriptions – Molina Investigation – Respondent Cortez-Gomez)**

3 158. Respondent Cortez-Gomez is subject to disciplinary action under Code section  
4 4301, subdivisions (j) and/or (o), for violating, for Code sections 4059 and 4063, and section  
5 1716 of Title 16 of the California Code of Regulations by dispensing and billing unauthorized  
6 prescriptions with respect to Rx # 321107, Rx # 281475, Rx # 278600, Rx # 306678, Rx #  
7 285437, and Rx # 285438, described in the paragraphs above and incorporated herein as though  
8 set forth in full.

9 **FORTY-NINTH CAUSE FOR DISCIPLINE**

10 **(Unprofessional Conduct – Molina Investigation – Respondent Cortez-Gomez)**

11 159. Respondent Cortez-Gomez is subject to disciplinary action under Code section  
12 4301 for unprofessional conduct for dispensing and billing unauthorized prescriptions with  
13 respect to Rx # 321107, Rx # 281475, Rx # 278600, Rx # 306678, Rx # 285437, and Rx #  
14 285438, described in the paragraphs above and incorporated herein as though set forth in full

15 **FIFTIETH CAUSE FOR DISCIPLINE**

16 **(Uncertain Prescription – La Mesa Cardiac Investigation – Respondent Cortez-Gomez)**

17 160. Respondent Cortez-Gomez is subject to disciplinary action under Code section  
18 4301, subdivisions (j) and/or (o), for violating, for Code section 4040(a)(1)(C), and section 1761  
19 of Title 16 of the California Code of Regulations for dispensing a prescription which contained a  
20 significant error, omission, irregularity, uncertainty, or ambiguity, with respect to Rx # 173562,  
21 described in the paragraphs above and incorporated herein as though set forth in full.

22 **FIFTY-FIRST CAUSE FOR DISCIPLINE**

23 **(Unprofessional Conduct – La Mesa Cardiac Investigation – Respondent Cortez-Gomez)**

24 161. Respondent Cortez-Gomez is subject to disciplinary action under Code section  
25 4301 for unprofessional conduct for dispensing a prescription which contained a significant error,  
26 omission, irregularity, uncertainty, or ambiguity, with respect to Rx # 173562, described in the  
27 paragraphs above and incorporated herein as though set forth in full.

28 ///

**OTHER MATTERS**

1  
2           162. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit No. PHY  
3 53746 issued to Talami International, Inc., dba Palm Care Pharmacy, then Talami International,  
4 Inc. shall be prohibited from serving as a manager, administrator, owner, member, officer,  
5 director, associate, partner, or in any position with management or control of a license for five  
6 years if Pharmacy Permit Number PHY 53746 is placed on probation or until Pharmacy Permit  
7 Number 53746 is reinstated if it is revoked.

8           163. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit No. PHY  
9 53746 issued to Talami International, Inc., dba Palm Care Pharmacy, and Usama Alkazaki had  
10 knowledge of, or knowingly participated in, the conduct for which the license is disciplined, then  
11 Usama Alkazaki shall be prohibited from serving as a manager, administrator, owner, member,  
12 officer, director, associate, partner, or in any position with management or control of a license for  
13 five years if Pharmacy Permit Number PHY 53746 is placed on probation or until Pharmacy  
14 Permit Number 53746 is reinstated if it is revoked.

15           164. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit No. PHY  
16 53746 issued to Talami International, Inc., dba Palm Care Pharmacy, and Sarah Adel  
17 Abdulkareem Kala had knowledge of, or knowingly participated in, the conduct for which the  
18 license is disciplined, then Sarah Adel Abdulkareem Kala shall be prohibited from serving as a  
19 manager, administrator, owner, member, officer, director, associate, partner, or in any position  
20 with management or control of a license for five years if Pharmacy Permit Number PHY 53746 is  
21 placed on probation or until Pharmacy Permit Number 53746 is reinstated if it is revoked.

22           165. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit No. PHY  
23 53746 issued to Talami International, Inc., dba Palm Care Pharmacy, and Brenda Ofelia Cortez-  
24 Gomez had knowledge of, or knowingly participated in, the conduct for which the license is  
25 disciplined, then Brenda Ofelia Cortez-Gomez shall be prohibited from serving as a manager,  
26 administrator, owner, member, officer, director, associate, partner, or in any position with  
27 management or control of a license for five years if Pharmacy Permit Number PHY 53746 is  
28 placed on probation or until Pharmacy Permit Number 53746 is reinstated if it is revoked.

1           166. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit No. PHY  
2 56207 issued to Talami Health Care LLC, dba Palm Care Pharmacy, then Talami Health Care  
3 LLC shall be prohibited from serving as a manager, administrator, owner, member, officer,  
4 director, associate, partner, or in any position with management or control of a license for five  
5 years if Pharmacy Permit Number PHY 56207 is placed on probation or until Pharmacy Permit  
6 Number 56207 is reinstated if it is revoked.

7           167. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit No. PHY  
8 56207 issued to Talami Health Care LLC, dba Palm Care Pharmacy, and Usama Alkazaki had  
9 knowledge of, or knowingly participated in, the conduct for which the license is disciplined, then  
10 Usama Alkazaki shall be prohibited from serving as a manager, administrator, owner, member,  
11 officer, director, associate, partner, or in any position with management or control of a license for  
12 five years if Pharmacy Permit Number PHY 56207 is placed on probation or until Pharmacy  
13 Permit Number 56207 is reinstated if it is revoked.

14 ///

15 ///

16 ///

17 ///

18 ///

19 ///

20 ///

21 ///

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///

1 168. Pursuant to Code section 4307, if discipline is imposed on Pharmacist License No.  
2 RPH 69696 issued to Usama Alkazaki, then Usama Alkazaki shall be prohibited from serving as  
3 a manager, administrator, owner, member, officer, director, associate, partner, or in any position  
4 with management or control of a license for five years if Pharmacist License No. RPH 69696 is  
5 placed on probation or until Pharmacist License No. RPH 6969 is reinstated if it is revoked.

6 169. Pursuant to Code section 4307, if discipline is imposed on Pharmacist License No.  
7 RPH 76476 issued to Sarah Adel Abdulkareem Kala, then Sarah Adel Abdulkareem Kala shall be  
8 prohibited from serving as a manager, administrator, owner, member, officer, director, associate,  
9 partner, or in any position with management or control of a license for five years if Pharmacist  
10 License No. RPH 76476 is placed on probation or until Pharmacist License No. RPH 76476 is  
11 reinstated if it is revoked.

12 170. Pursuant to Code section 4307, if discipline is imposed on Pharmacist License No.  
13 RPH 67947 issued to Brenda Ofelia Cortez-Gomez, then Brenda Ofelia Cortez-Gomez shall be  
14 prohibited from serving as a manager, administrator, owner, member, officer, director, associate,  
15 partner, or in any position with management or control of a license for five years if Pharmacist  
16 License No. RPH 67947 is placed on probation or until Pharmacist License No. RPH 67947 is  
17 reinstated if it is revoked.

### 18 **DISCIPLINE CONSIDERATIONS**

19 171. To determine the degree of discipline, if any, to be imposed on Respondent Talami  
20 International, Inc., dba Palm Care Pharmacy, Complainant alleges that on or about December 4,  
21 2018, in a prior action, the Board of Pharmacy issued Citation Number CI 2016 74625 for  
22 violating section 1746.1, subsection (b)(4), of Title 16 of the California Code of Regulations,  
23 protocol for furnishing self-administered hormonal contraception. That Citation is now final.

24 172. To determine the degree of discipline, if any, to be imposed on Respondent Usama  
25 Alkazaki, Complainant alleges that on or about February 4, 2018, in a prior action, the Board of  
26 Pharmacy issued Citation Number CI 2018 82126 for violating section 1746.1, subsection (b)(4),  
27 of Title 16 of the California Code of Regulations, protocol for furnishing self-administered  
28 hormonal contraception. That Citation is now final.



1 **SECOND AMENDED STATEMENT OF ISSUES AGAINST:**

2 **DREAM BORDER VILLAGE, LLC, DBA PALM CARE PHARMACY 1005**

3 175. Respondent Dream Border Village, LLC, dba Palm Care Pharmacy 1005 submitted  
4 an application for a community pharmacy permit to the Board. In its application, Palm Care  
5 Pharmacy 1005 identified Amjad A. Alqazqi, who is the brother of Respondent Alkazaki, as  
6 being the sole owner and managing member of Respondent Dream Border Village, LLC.  
7 However, Palm Care Pharmacy 1005 is identified as one of the pharmacies owned by Respondent  
8 Alkazaki on Respondent Palm Care Pharmacy’s website, Amjad A. Alqazqi is an employee of  
9 Respondent Palm Care Pharmacy, Palm Care Pharmacy 1005’s address and telephone number are  
10 identical to the address and telephone number for Talami International Health, LLC’s pharmacy,  
11 and a staff pharmacist of Respondent Palm Care Pharmacy was designated as the Pharmacist-in-  
12 Charge of Palm Care Pharmacy 1005.

13 176. Respondent Dream Border Village, LLC dba Palm Care Pharmacy 1005 did not  
14 disclose that Respondent Alkazaki, who was under multiple Board investigations with a pending  
15 accusation filed against his license and Respondent Palm Care Pharmacy’s license, was actually  
16 the owner of and/or held management or control over Respondent Dream Border Village, dba  
17 Palm Care Pharmacy 1005; exhibited by actions including, arranging for Respondent Palm Care  
18 Pharmacy, 1005 to share a lease or premises with Talami, International Health LLC, Palm Care  
19 Pharmacy, owned by Respondent Alkazaki, and advertising that Palm Care Pharmacy 1005 as  
20 included within Respondent Alkazaki’s chain of pharmacies.

21 **CAUSES FOR DENIAL**

22 **FIRST CAUSE FOR DENIAL OF APPLICATION**

23 (Unprofessional Conduct)

24 177. The application of Dream Border Village, LLC, dba Palm Care Pharmacy 1005 is  
25 subject to denial under sections 4300, subdivision (c), section 4301, and section 4302, for the  
26 facts alleged in paragraphs 175 and 176, and for unprofessional conduct as alleged in the above  
27 paragraphs of the Third Amended Accusation, which are incorporated herein as though set forth  
28 in full.

1 **SECOND CAUSE FOR DENIAL OF APPLICATION**

2 (Grounds for Discipline or Discipline Based on Professional Misconduct)

3 178. The application of Dream Border Village, LLC, dba Palm Care Pharmacy 1005 is  
4 subject to denial under section 4302 for the existence of conditions that would constitute grounds  
5 for disciplinary action, or for an actual record of formal discipline based on professional  
6 misconduct, for the facts alleged in paragraphs 175 and 176, and for unprofessional conduct as  
7 alleged in the above paragraphs of the Third Amended Accusation, which are incorporated herein  
8 as though set forth in full.

9 **PRAYER**

10 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,  
11 and that following the hearing, the Board of Pharmacy issue a decision:

12 1. Revoking or suspending Original Pharmacy Permit Number PHY 53746, issued to  
13 Talami International, Inc., dba Palm Care Pharmacy; Usama Alkazaki, CEO/Secretary/CFO;

14 2. Revoking or suspending Original Pharmacy Permit Number PHY 56207, issued to  
15 Talami Health Care LLC, dba Palm Care Pharmacy; Usama Alkazaki, Member;

16 3. Revoking or suspending Pharmacist License Number RPH 69696, issued to Usama  
17 Alkazaki;

18 4. Revoking or suspending Advance Practice Pharmacist License Number APH 10659,  
19 issued to Usama Alkazaki;

20 5. Revoking or suspending Pharmacist License Number RPH 76476, issued to Sarah  
21 Adel Abdulkareem Kala;

22 6. Revoking or suspending Pharmacist License Number RPH 67947, issued to Brenda  
23 Ofelia Cortez-Gomez;

24 ///

25 ///

26 ///

27 ///

28 ///

1           7.     Prohibiting Talami International, Inc. from serving as a manager, administrator,  
2 owner, member, officer, director, associate, partner, or in any position with management or  
3 control of a license for five years if Pharmacy Permit Number 53746, issued to Talami  
4 International, Inc., dba Palm Care Pharmacy, is placed on probation or until Pharmacy Permit  
5 Number 53746 is reinstated if it is revoked;

6           8.     Prohibiting Talami Health Care LLC from serving as a manager, administrator,  
7 owner, member, officer, director, associate, partner, or in any position with management or  
8 control of a license for five years if Pharmacy Permit Number 56207, issued to Talami Health  
9 Care LLC, dba Palm Care Pharmacy, is placed on probation or until Pharmacy Permit Number  
10 56207 is reinstated if it is revoked;

11          9.     Prohibiting Usama Alkazaki from serving as a manager, administrator, owner,  
12 member, officer, director, associate, partner, or in any position with management or control of a  
13 license for five years if any of Pharmacist License Number RPH 69696, or Pharmacy Permit  
14 Number 53746, issued to Talami International, Inc., dba Palm Care Pharmacy, or Pharmacy  
15 Permit Number 56207, issued to Talami Health Care LLC, is placed on probation or until  
16 Pharmacist License Number RPH 69696, Pharmacy Permit Number 53746, and Pharmacy Permit  
17 56207 are reinstated if any are revoked;

18          10.    Prohibiting Sarah Adel Abdulkareem Kala from serving as a manager, administrator,  
19 owner, member, officer, director, associate, partner, or in any position with management or  
20 control of a license for five years if either Pharmacist License Number RPH 76476 or Pharmacy  
21 Permit Number 53746, issued to Talami International, Inc., dba Palm Care Pharmacy, is placed  
22 on probation or until both Pharmacist License Number RPH 76476 and Pharmacy Permit Number  
23 53746 are reinstated if either or both are revoked;

24          11.    Prohibiting Brenda Ofelia Cortez-Gomez from serving as a manager, administrator,  
25 owner, member, officer, director, associate, partner, or in any position with management or  
26 control of a license for five years if either Pharmacist License Number RPH 67947 or Pharmacy  
27 Permit Number 53746, issued to Talami International, Inc., dba Palm Care Pharmacy, is placed  
28 on probation or until both Pharmacist License Number RPH 67947 and Pharmacy Permit Number



1 53746 are reinstated if either or both are revoked;

2 12. Ordering Talami International, Inc., dba Palm Care Pharmacy, Talami Health Care  
3 LLC, dba Palm Care Pharmacy, Usama Alkazaki, Sarah Adel Abdulkareem Kala, and Brenda  
4 Ofelia Cortez-Gomez to pay the Board of Pharmacy the reasonable costs of the investigation and  
5 enforcement of this case, pursuant to Business and Professions Code section 125.3;

6 13. Denying the application of Talami International Health LLC, dba Palm Care  
7 Pharmacy, Usama Alkazaki, Manager/CEO;

8 14. Denying the application of Dream Border Village LLC, dba Palm Care Pharmacy  
9 1005; and,

10 15. Taking such other and further action as deemed necessary and proper.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

DATED: 5/30/2024

**Sodergren,** Digitally signed by  
**Anne@DCA** Sodergren, Anne@DCA  
Date: 2024.05.30  
09:29:45 -07'00'

\_\_\_\_\_  
ANNE SODERGREN  
Executive Officer  
Board of Pharmacy  
Department of Consumer Affairs  
State of California  
*Complainant*

SD2020801187  
84546844.docx